SHADOWLEE personal page - To The Moon

SHADOWLEE

SHADOWLEE

No personal profile

10Follow

0Followers

0Topic

0Badge

2021-06-29

good

Sorry, the original content has been removed

2021-06-25

oh

A brief discussion on the valuation bubble of CXO track

2021-06-25

look

XPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39

2021-06-17

up

Funds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies

2021-06-10

hi ,nice to meet here

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586297136997911","uuid":"3586297136997911","gmtCreate":1623203112373,"gmtModify":1623896167382,"name":"SHADOWLEE","pinyin":"shadowlee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":159938617,"gmtCreate":1624934785339,"gmtModify":1703848316585,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586297136997911","idStr":"3586297136997911"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159938617","repostId":"1104770632","repostType":4,"repost":{"id":"1104770632","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624927163,"share":"https://ttm.financial/m/news/1104770632?lang=en_US&edition=fundamental","pubTime":"2021-06-29 08:39","market":"hk","language":"zh","title":"Nayuki's tea lottery winning rate is 8%, and 40 lots are subscribed to secure one lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1104770632","media":"老虎资讯综合","summary":"6月29日消息，本周二奈雪的茶发布公告，公司发行2.57亿股股份，每股定价19.8港元，每手500股，预期将于6月30日上市。分配结果：\n甲组每手500股，一手中签率8%，认购40手稳中一手。\n乙组头","content":"<p>News on June 29, this Tuesday<a href=\"https://laohu8.com/S/02150\">Nayuki's tea</a>According to the announcement, the company issued 257 million shares, priced at HK $19.8 per share, with 500 shares per lot, and is expected to be listed on June 30.<img src=\"https://static.tigerbbs.com/6af239b570522de01079011982ac9576\" tg-width=\"661\" tg-height=\"550\" referrerpolicy=\"no-referrer\"><b>Distribution result:</b></p><p>Group A has 500 shares per lot, and the winning rate of one lot is 8%. If you subscribe for 40 lots, you will secure one lot.</p><p>The head of Group B is 300,000 shares (600 lots), and 3,000 shares (6 lots) are allocated.<img src=\"https://static.tigerbbs.com/d1861f115ef2892bc51ce6b5f05ff7b8\" tg-width=\"536\" tg-height=\"629\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5f27f80d6ce9a1fdc75d8516bf6b6ffe\" tg-width=\"543\" tg-height=\"741\" referrerpolicy=\"no-referrer\">During the public offering stage, Nayuki's tea was subscribed 432.03 times, and the final number of offer shares allocated to the public offering was 129 million shares, accounting for 50% of the total number of offer shares (before any over-allotment option is exercised). A total of 642,033 valid applications were received.</p><p>In addition, the international offering was significantly oversubscribed, and the final number of offer shares was 129 million shares (excluding over-allocation shares), equivalent to 50% of the total number of offer shares.</p><p>In terms of fund-raising purposes, the company intends to use the net proceeds received from the global offering estimated to be approximately HK $4.84 billion (assuming that the over-allotment option is not exercised) for the following purposes: approximately 70.0% will be used to expand the tea shop network in the next three years and increase its market penetration; Approximately 10.0% will be used in the next three years to further improve overall operations by strengthening technical capabilities to improve operational efficiency; About 10.0% will be used to improve supply chain capabilities in the next three years to support the company's scale expansion; Approximately 10.0% will be used for working capital and general corporate purposes.</p><p>It is reported that Naixue's tea shop operated by the company is China's leading high-end ready-made tea chain store, focusing on providing ready-made tea drinks. According to CIC, Nayuki's tea is the second largest teahouse brand in China's high-end ready-made teahouse market in terms of total retail consumption in 2020, with a market share of 18.9%. In terms of total retail consumption in 2020, Nayuki's tea is the seventh largest teahouse brand in China's overall ready-made teahouse industry, with a market share of 3.9%.</p><p>In order to enhance the convenience and personalized experience of Nayuki's tea to customers, the company launched Nayuki's tea membership system and Nayuki's tea application, and achieved full integration with the company's Nayuki's tea shop network. The company's Nayuki tea membership system has about 34.7 million registered members. In 2020, approximately 49.0% of Nayuki's total tea orders came from Nayuki's tea members.</p><p>The number of Nayuki's teahouses grew rapidly from 44 as of December 31, 2017 to 491 as of December 31, 2020, and further to 562 as of the Latest Practicable Date. The revenue generated by the company's Nayuki teahouse increased from RMB 910 million in 2018 to RMB 2.292 billion in 2019, and further increased to RMB 2.871 billion in 2020.</p><p>In addition, in terms of same stores in 2018 and 2019, Nayuki's tea same store profit margin remained stable in 2018 and 2019, at 24.9% and 25.3%, respectively. Due to the impact of the COVID-19 outbreak, in terms of same stores in 2019 and 2020, Nayuki's tea same store profit margin was 13.5% in 2020, compared to 21.0% in 2019.</p><p>Throughout the track record period, the company's profitability continued to improve, with total revenue increasing from 1.087 billion yuan in 2018 to 3.057 billion yuan in 2020, with a compound annual growth rate of 67.7% from 2018 to 2020; The adjusted net loss decreased significantly from RMB 56.58 million in 2018 to RMB 11.735 million in 2019, and further reversed to an adjusted net profit of RMB 16.643 million in 2020.</p><p>In the first nine months of 2020, the company recorded revenue of 2.115 billion yuan and adjusted net profit of 4.484 million yuan. Under the influence of the epidemic, the domestic food industry has been greatly impacted. The company's adjusted net profit has narrowed under pressure, but its revenue still maintains a strong growth momentum.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nayuki's tea lottery winning rate is 8%, and 40 lots are subscribed to secure one lot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNayuki's tea lottery winning rate is 8%, and 40 lots are subscribed to secure one lot\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-29 08:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>News on June 29, this Tuesday<a href=\"https://laohu8.com/S/02150\">Nayuki's tea</a>According to the announcement, the company issued 257 million shares, priced at HK $19.8 per share, with 500 shares per lot, and is expected to be listed on June 30.<img src=\"https://static.tigerbbs.com/6af239b570522de01079011982ac9576\" tg-width=\"661\" tg-height=\"550\" referrerpolicy=\"no-referrer\"><b>Distribution result:</b></p><p>Group A has 500 shares per lot, and the winning rate of one lot is 8%. If you subscribe for 40 lots, you will secure one lot.</p><p>The head of Group B is 300,000 shares (600 lots), and 3,000 shares (6 lots) are allocated.<img src=\"https://static.tigerbbs.com/d1861f115ef2892bc51ce6b5f05ff7b8\" tg-width=\"536\" tg-height=\"629\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/5f27f80d6ce9a1fdc75d8516bf6b6ffe\" tg-width=\"543\" tg-height=\"741\" referrerpolicy=\"no-referrer\">During the public offering stage, Nayuki's tea was subscribed 432.03 times, and the final number of offer shares allocated to the public offering was 129 million shares, accounting for 50% of the total number of offer shares (before any over-allotment option is exercised). A total of 642,033 valid applications were received.</p><p>In addition, the international offering was significantly oversubscribed, and the final number of offer shares was 129 million shares (excluding over-allocation shares), equivalent to 50% of the total number of offer shares.</p><p>In terms of fund-raising purposes, the company intends to use the net proceeds received from the global offering estimated to be approximately HK $4.84 billion (assuming that the over-allotment option is not exercised) for the following purposes: approximately 70.0% will be used to expand the tea shop network in the next three years and increase its market penetration; Approximately 10.0% will be used in the next three years to further improve overall operations by strengthening technical capabilities to improve operational efficiency; About 10.0% will be used to improve supply chain capabilities in the next three years to support the company's scale expansion; Approximately 10.0% will be used for working capital and general corporate purposes.</p><p>It is reported that Naixue's tea shop operated by the company is China's leading high-end ready-made tea chain store, focusing on providing ready-made tea drinks. According to CIC, Nayuki's tea is the second largest teahouse brand in China's high-end ready-made teahouse market in terms of total retail consumption in 2020, with a market share of 18.9%. In terms of total retail consumption in 2020, Nayuki's tea is the seventh largest teahouse brand in China's overall ready-made teahouse industry, with a market share of 3.9%.</p><p>In order to enhance the convenience and personalized experience of Nayuki's tea to customers, the company launched Nayuki's tea membership system and Nayuki's tea application, and achieved full integration with the company's Nayuki's tea shop network. The company's Nayuki tea membership system has about 34.7 million registered members. In 2020, approximately 49.0% of Nayuki's total tea orders came from Nayuki's tea members.</p><p>The number of Nayuki's teahouses grew rapidly from 44 as of December 31, 2017 to 491 as of December 31, 2020, and further to 562 as of the Latest Practicable Date. The revenue generated by the company's Nayuki teahouse increased from RMB 910 million in 2018 to RMB 2.292 billion in 2019, and further increased to RMB 2.871 billion in 2020.</p><p>In addition, in terms of same stores in 2018 and 2019, Nayuki's tea same store profit margin remained stable in 2018 and 2019, at 24.9% and 25.3%, respectively. Due to the impact of the COVID-19 outbreak, in terms of same stores in 2019 and 2020, Nayuki's tea same store profit margin was 13.5% in 2020, compared to 21.0% in 2019.</p><p>Throughout the track record period, the company's profitability continued to improve, with total revenue increasing from 1.087 billion yuan in 2018 to 3.057 billion yuan in 2020, with a compound annual growth rate of 67.7% from 2018 to 2020; The adjusted net loss decreased significantly from RMB 56.58 million in 2018 to RMB 11.735 million in 2019, and further reversed to an adjusted net profit of RMB 16.643 million in 2020.</p><p>In the first nine months of 2020, the company recorded revenue of 2.115 billion yuan and adjusted net profit of 4.484 million yuan. Under the influence of the epidemic, the domestic food industry has been greatly impacted. The company's adjusted net profit has narrowed under pressure, but its revenue still maintains a strong growth momentum.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/969153dc5674369c3b376e33d2fc3976","relate_stocks":{"02150":"奈雪的茶"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104770632","content_text":"6月29日消息，本周二奈雪的茶发布公告，公司发行2.57亿股股份，每股定价19.8港元，每手500股，预期将于6月30日上市。分配结果：\n甲组每手500股，一手中签率8%，认购40手稳中一手。\n乙组头为30万股（600手），获配3000股（6手）。公开发售阶段奈雪的茶获432.03倍认购，分配至公开发售的发售股份最终数目为1.29亿股，占发售股份总数的50%（任何超额配股权获行使前）。合共接获642033份有效申请。\n此外，国际发售获大幅超额认购，发售股份最终数目为1.29亿股（不包括超额分配股份），相当于发售股份总数的50%。\n筹资用途方面，公司拟将收取的全球发售所得款项净额估计约48.4亿港元（假设超额配股权并无获行使）用于以下用途：约70.0%将在未来三年用于扩张茶饮店网络并提高其市场渗透率；约10.0%将在未来三年用于通过强化技术能力，进一步提升整体运营，以提升运营效率；约10.0%将在未来三年用于提升供应链能力，以支持公司的规模扩张；约10.0%将用作营运资金及作一般企业用途。\n据悉，公司所经营的奈雪的茶茶饮店是中国领先的高端现制茶饮连锁店，专注于提供现制茶饮。根据灼识谘询的资料，按2020年零售消费总值计，奈雪的茶在中国高端现制茶饮店市场中为第二大茶饮店品牌，市场份额为18.9%。按2020年零售消费总值计，奈雪的茶在中国整体现制茶饮店行业中为第七大茶饮店品牌，市场份额为3.9%。\n为提升奈雪的茶对客户的便利性及个性化体验，公司推出奈雪的茶会员体系及奈雪的茶应用程序，并实现与公司奈雪的茶茶饮店网络的全面整合。公司的奈雪的茶会员体系有注册会员约3470万名。于2020年，奈雪的茶订单总数中约49.0%来自奈雪的茶会员。\n奈雪的茶茶饮店数量由截至2017年12月31日的44间迅速增长至截至2020年12月31日的491间，并于截至最后实际可行日期进一步增至562间。公司的奈雪的茶茶饮店所产生的收益由2018年的人民币9.1亿元增至2019年的人民币22.92亿元，并进一步增至2020年的人民币28.71亿元。\n此外，就2018年及2019年的同店而言，奈雪的茶同店利润率于2018年及2019年维持稳定，分别为24.9%及25.3%。由于COVID-19爆发的影响，就2019年及2020年的同店而言，奈雪的茶同店利润率于2020年为13.5%，而2019年为21.0%。\n于整个往绩记录期间，公司的盈利能力不断提升，总营收由2018年的10.87亿元提升至2020年的30.57亿元人民币，2018~2020年的复合年增长率达67.7%；经调整净亏损由2018年的人民币5658万元大幅减少至2019年的人民币1173.5万元，并进一步扭转为2020年的经调整净利润1664.3万元人民币。\n2020年前9个月，公司录得收入21.15亿元，经调整净利润448.4万元。在疫情影响下，国内食品行业受到较大冲击，公司经调整净利润承压收窄，但营收仍保持强劲增长势头。","news_type":1,"symbols_score_info":{"02150":0.9}},"isVote":1,"tweetType":1,"viewCount":1643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122303537,"gmtCreate":1624595733929,"gmtModify":1703841326454,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586297136997911","idStr":"3586297136997911"},"themes":[],"htmlText":"oh","listText":"oh","text":"oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122303537","repostId":"1198330093","repostType":4,"repost":{"id":"1198330093","kind":"news","weMediaInfo":{"introduction":"民间投资共享平台——汇集投资高手，发现投资好点子。","home_visible":1,"media_name":"阿尔法工场研究院","id":"1026500124","head_image":"https://static.tigerbbs.com/4df70e92a2d64be896797ea06b5e676a"},"pubTimestamp":1624588229,"share":"https://ttm.financial/m/news/1198330093?lang=en_US&edition=fundamental","pubTime":"2021-06-25 10:30","market":"sh","language":"zh","title":"A brief discussion on the valuation bubble of CXO track","url":"https://stock-news.laohu8.com/highlight/detail?id=1198330093","media":"阿尔法工场研究院","summary":"随着CXO渗透率的提高，未来行业增速将快速下降。\n聊之前，先说结论：目前无论你持有哪一只CXO股票，现在的一两百的pe，估值明显都已经是泡沫了，但泡沫不意味着要你止盈，只是要给大家提个醒，对未来期望有","content":"<p><img src=\"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29\" tg-width=\"1080\" tg-height=\"721\" referrerpolicy=\"no-referrer\"><b>As the penetration rate of CXO increases, the growth rate of the industry will decline rapidly in the future.</b></p><p>Before chatting, let's talk about the conclusion: No matter which CXO stock you hold at present, the current pe of one or two hundred, the valuation is obviously a bubble, but the bubble does not mean that you need to take profits, but just to remind everyone. Wake up, have correct psychological expectations for future expectations.</p><p>The CXO track has undoubtedly been one of the highest quality tracks in A-shares in recent years, and one of these can even be removed.</p><p>The rapid development of domestic CXO gods in recent years has benefited from these factors: First, engineer dividends. The supply of undergraduate, master's and doctoral degrees in China is blowout and the labor cost is relatively low (only equivalent to 30%-50% of that in European and American countries). In addition, in recent years, leading talents in overseas related fields have returned to China to start businesses. The combination of the two has outstanding advantages.</p><p>2. The penetration rate of China's pharmaceutical outsourcing market was low in the past few years, and it was only about 35% in 2018.</p><p>3. Industrial transfer of international pharmaceutical R&D outsourcing services, but judging from the current increasing costs, the future speed of industrial transfer needs to be questioned.</p><p>4. In recent years, capital has invested crazily in domestic innovative drug companies.</p><p>There is no need to talk about other fundamentals in detail. Let's take a look at the future development potential.</p><p><b>01</b></p><p>The growth of CXO is closely related to the growth of innovative drug companies.<b>To judge the golden cycle of CXO, it must be inseparable from the development and growth cycle of innovative drugs.</b></p><p>From the perspective of mature foreign markets, the growth rate of drugs under development matches the growth rate of CXO. Let's take a look at the global and Chinese pharmaceutical market size:</p><p><img src=\"https://static.tigerbbs.com/97773744b4b5641959840aaa0410f500\" tg-width=\"516\" tg-height=\"348\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7b8157b70922b8885798ae8bec9850cf\" tg-width=\"514\" tg-height=\"341\" referrerpolicy=\"no-referrer\">The global pharmaceutical market size in 2016 was US $1,153.6 billion, and is expected to reach US $1,475.1 billion in 2021, with a compound growth rate of approximately 5%.</p><p>From a geographical point of view, the United States is still the largest pharmaceutical market in the world. In 2016, the US market accounted for approximately 38% of the global market during the same period. As the world's largest emerging market, China's market size has maintained rapid growth in recent years as demand has continued to increase. It is expected to reach US $178.2 billion by 2021, with a growth rate of about 8%.</p><p>Let's take a look at the financing situation of domestic biotechnology companies in recent years. The high point of financing and the high point of pharmaceutical outsourcing growth should be obviously correlated. As you can see from the figure below, 2019 and 2020 are the peak periods of financing, and the two years after the peak of financing should also be the peak of CXO track growth.<img src=\"https://static.tigerbbs.com/77382e31cfaea57bcbe2a6d0e0fd118c\" tg-width=\"506\" tg-height=\"349\" referrerpolicy=\"no-referrer\">Visually, 2020 and 2021 in the figure below will be the peak of domestic CXO performance growth.<img src=\"https://static.tigerbbs.com/9abb7b6623e38f03db5ab2fe4ec70af3\" tg-width=\"516\" tg-height=\"354\" referrerpolicy=\"no-referrer\">Let's take a look at the role of pharmaceutical outsourcing services while the pharmaceutical market is developing. At present, the penetration rate of foreign pharmaceutical R&D outsourcing has reached about 55%, while the penetration rate of domestic pharmaceutical R&D outsourcing is still around 40% to 45%.</p><p>That is to say, if there is no foreign market, then there is still 10 to 15% potential for domestic pharmaceutical outsourcing to be tapped in the future.</p><p>Judging from the actual penetration rate and expectations of pharmaceutical R&D outsourcing development, the growth exceeded expectations.<b>The ceiling for future development should be very low.</b>Some industry insiders predict that the penetration rate ceiling will be around 60% to 65% or even lower.<img src=\"https://static.tigerbbs.com/242f24b01dd6070eb041e944988dc3df\" tg-width=\"558\" tg-height=\"351\" referrerpolicy=\"no-referrer\">To add a picture of the penetration rate of domestic pharmaceutical outsourcing, I think it is a bit underestimated based on other data.<img src=\"https://static.tigerbbs.com/0b764f34f3aad9e995adfc0b88e3b44c\" tg-width=\"649\" tg-height=\"454\" referrerpolicy=\"no-referrer\"><b>The foreign pharmaceutical outsourcing market is already very mature. Compared with the domestic market, the growth rate of the track is much lower. According to authoritative data, the growth rate of CXO in a mature market is about 10%.</b></p><p><b>02</b></p><p>The global pharmaceutical outsourcing market exceeds US $100 billion, of which the chemical drug C (D) MO market accounts for the largest share, and the biological drug C (D) MO has the fastest growth rate. It is reported that the average annual compound growth rate from 2013 to 2017 is 10.3%, and the overall growth of the global pharmaceutical outsourcing market is steady.</p><p>The overall market size reached US $104.1 billion in 2017, of which the CRO market size was US $44.6 billion, accounting for 43%, and the C (D) MO market size was US $59.5 billion, accounting for 57%.</p><p>In the next five years, the global CRO + C (D) MO industry will continue to maintain rapid growth. In 2022, the scale of the global pharmaceutical outsourcing industry will reach US $178.4 billion, with an average annual compound growth rate of 11.4%.<img src=\"https://static.tigerbbs.com/18fba7f0a1b0e11022ec40ea3a216aba\" tg-width=\"499\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d15886781297933be5997e460da5d6e6\" tg-width=\"503\" tg-height=\"375\" referrerpolicy=\"no-referrer\">The scale of pharmaceutical outsourcing in China is expected to grow as follows, with an average annual growth rate of about 12%.<img src=\"https://static.tigerbbs.com/7c08a2a436bd1d9a1c8d15a883425160\" tg-width=\"510\" tg-height=\"358\" referrerpolicy=\"no-referrer\">One more thing, if we look at the sub-industries of CXO, there are two aspects worthy of everyone's attention: First, whether CRO companies are in the past or in the future<b>The development trend is far less than that of CDMO companies</b>； Second, the future competitiveness of CXO companies whose main income comes from international sources is far greater than that of companies with a low proportion of international income.</p><p>I won't go into details here. The pictures below are for your reference.<img src=\"https://static.tigerbbs.com/9e5ac5dd0c02a7acfe64445230f1c9e2\" tg-width=\"793\" tg-height=\"757\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/4d5a5959082d1d943a32d3d125279c3a\" tg-width=\"770\" tg-height=\"545\" referrerpolicy=\"no-referrer\">To sum up, there are two main factors in the global pharmaceutical market, including the Chinese market, that determine the future growth of the CXO track: First, the scale growth of the pharmaceutical market, especially the growth rate of innovative drug development; Second, the penetration rate of the pharmaceutical outsourcing market has increased. The growth rate of the global pharmaceutical market is expected to be 5%, and that of China is 8%. The current penetration rate is 55% globally and about 40% to 45% in China. At this point, the conclusion is self-evident.</p><p>Except for the top few first-line and highest-quality CXO companies, everyone else is doing it and cherishing it.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A brief discussion on the valuation bubble of CXO track</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA brief discussion on the valuation bubble of CXO track\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1026500124\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/4df70e92a2d64be896797ea06b5e676a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">阿尔法工场研究院 </p>\n<p class=\"h-time smaller\">2021-06-25 10:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29\" tg-width=\"1080\" tg-height=\"721\" referrerpolicy=\"no-referrer\"><b>As the penetration rate of CXO increases, the growth rate of the industry will decline rapidly in the future.</b></p><p>Before chatting, let's talk about the conclusion: No matter which CXO stock you hold at present, the current pe of one or two hundred, the valuation is obviously a bubble, but the bubble does not mean that you need to take profits, but just to remind everyone. Wake up, have correct psychological expectations for future expectations.</p><p>The CXO track has undoubtedly been one of the highest quality tracks in A-shares in recent years, and one of these can even be removed.</p><p>The rapid development of domestic CXO gods in recent years has benefited from these factors: First, engineer dividends. The supply of undergraduate, master's and doctoral degrees in China is blowout and the labor cost is relatively low (only equivalent to 30%-50% of that in European and American countries). In addition, in recent years, leading talents in overseas related fields have returned to China to start businesses. The combination of the two has outstanding advantages.</p><p>2. The penetration rate of China's pharmaceutical outsourcing market was low in the past few years, and it was only about 35% in 2018.</p><p>3. Industrial transfer of international pharmaceutical R&D outsourcing services, but judging from the current increasing costs, the future speed of industrial transfer needs to be questioned.</p><p>4. In recent years, capital has invested crazily in domestic innovative drug companies.</p><p>There is no need to talk about other fundamentals in detail. Let's take a look at the future development potential.</p><p><b>01</b></p><p>The growth of CXO is closely related to the growth of innovative drug companies.<b>To judge the golden cycle of CXO, it must be inseparable from the development and growth cycle of innovative drugs.</b></p><p>From the perspective of mature foreign markets, the growth rate of drugs under development matches the growth rate of CXO. Let's take a look at the global and Chinese pharmaceutical market size:</p><p><img src=\"https://static.tigerbbs.com/97773744b4b5641959840aaa0410f500\" tg-width=\"516\" tg-height=\"348\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7b8157b70922b8885798ae8bec9850cf\" tg-width=\"514\" tg-height=\"341\" referrerpolicy=\"no-referrer\">The global pharmaceutical market size in 2016 was US $1,153.6 billion, and is expected to reach US $1,475.1 billion in 2021, with a compound growth rate of approximately 5%.</p><p>From a geographical point of view, the United States is still the largest pharmaceutical market in the world. In 2016, the US market accounted for approximately 38% of the global market during the same period. As the world's largest emerging market, China's market size has maintained rapid growth in recent years as demand has continued to increase. It is expected to reach US $178.2 billion by 2021, with a growth rate of about 8%.</p><p>Let's take a look at the financing situation of domestic biotechnology companies in recent years. The high point of financing and the high point of pharmaceutical outsourcing growth should be obviously correlated. As you can see from the figure below, 2019 and 2020 are the peak periods of financing, and the two years after the peak of financing should also be the peak of CXO track growth.<img src=\"https://static.tigerbbs.com/77382e31cfaea57bcbe2a6d0e0fd118c\" tg-width=\"506\" tg-height=\"349\" referrerpolicy=\"no-referrer\">Visually, 2020 and 2021 in the figure below will be the peak of domestic CXO performance growth.<img src=\"https://static.tigerbbs.com/9abb7b6623e38f03db5ab2fe4ec70af3\" tg-width=\"516\" tg-height=\"354\" referrerpolicy=\"no-referrer\">Let's take a look at the role of pharmaceutical outsourcing services while the pharmaceutical market is developing. At present, the penetration rate of foreign pharmaceutical R&D outsourcing has reached about 55%, while the penetration rate of domestic pharmaceutical R&D outsourcing is still around 40% to 45%.</p><p>That is to say, if there is no foreign market, then there is still 10 to 15% potential for domestic pharmaceutical outsourcing to be tapped in the future.</p><p>Judging from the actual penetration rate and expectations of pharmaceutical R&D outsourcing development, the growth exceeded expectations.<b>The ceiling for future development should be very low.</b>Some industry insiders predict that the penetration rate ceiling will be around 60% to 65% or even lower.<img src=\"https://static.tigerbbs.com/242f24b01dd6070eb041e944988dc3df\" tg-width=\"558\" tg-height=\"351\" referrerpolicy=\"no-referrer\">To add a picture of the penetration rate of domestic pharmaceutical outsourcing, I think it is a bit underestimated based on other data.<img src=\"https://static.tigerbbs.com/0b764f34f3aad9e995adfc0b88e3b44c\" tg-width=\"649\" tg-height=\"454\" referrerpolicy=\"no-referrer\"><b>The foreign pharmaceutical outsourcing market is already very mature. Compared with the domestic market, the growth rate of the track is much lower. According to authoritative data, the growth rate of CXO in a mature market is about 10%.</b></p><p><b>02</b></p><p>The global pharmaceutical outsourcing market exceeds US $100 billion, of which the chemical drug C (D) MO market accounts for the largest share, and the biological drug C (D) MO has the fastest growth rate. It is reported that the average annual compound growth rate from 2013 to 2017 is 10.3%, and the overall growth of the global pharmaceutical outsourcing market is steady.</p><p>The overall market size reached US $104.1 billion in 2017, of which the CRO market size was US $44.6 billion, accounting for 43%, and the C (D) MO market size was US $59.5 billion, accounting for 57%.</p><p>In the next five years, the global CRO + C (D) MO industry will continue to maintain rapid growth. In 2022, the scale of the global pharmaceutical outsourcing industry will reach US $178.4 billion, with an average annual compound growth rate of 11.4%.<img src=\"https://static.tigerbbs.com/18fba7f0a1b0e11022ec40ea3a216aba\" tg-width=\"499\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d15886781297933be5997e460da5d6e6\" tg-width=\"503\" tg-height=\"375\" referrerpolicy=\"no-referrer\">The scale of pharmaceutical outsourcing in China is expected to grow as follows, with an average annual growth rate of about 12%.<img src=\"https://static.tigerbbs.com/7c08a2a436bd1d9a1c8d15a883425160\" tg-width=\"510\" tg-height=\"358\" referrerpolicy=\"no-referrer\">One more thing, if we look at the sub-industries of CXO, there are two aspects worthy of everyone's attention: First, whether CRO companies are in the past or in the future<b>The development trend is far less than that of CDMO companies</b>； Second, the future competitiveness of CXO companies whose main income comes from international sources is far greater than that of companies with a low proportion of international income.</p><p>I won't go into details here. The pictures below are for your reference.<img src=\"https://static.tigerbbs.com/9e5ac5dd0c02a7acfe64445230f1c9e2\" tg-width=\"793\" tg-height=\"757\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/4d5a5959082d1d943a32d3d125279c3a\" tg-width=\"770\" tg-height=\"545\" referrerpolicy=\"no-referrer\">To sum up, there are two main factors in the global pharmaceutical market, including the Chinese market, that determine the future growth of the CXO track: First, the scale growth of the pharmaceutical market, especially the growth rate of innovative drug development; Second, the penetration rate of the pharmaceutical outsourcing market has increased. The growth rate of the global pharmaceutical market is expected to be 5%, and that of China is 8%. The current penetration rate is 55% globally and about 40% to 45% in China. At this point, the conclusion is self-evident.</p><p>Except for the top few first-line and highest-quality CXO companies, everyone else is doing it and cherishing it.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198330093","content_text":"随着CXO渗透率的提高，未来行业增速将快速下降。\n聊之前，先说结论：目前无论你持有哪一只CXO股票，现在的一两百的pe，估值明显都已经是泡沫了，但泡沫不意味着要你止盈，只是要给大家提个醒，对未来期望有个正确的心理预期。\nCXO赛道这几年毫无疑问是A股无容置疑的最优质赛道之一，甚至可以把这个之一拿掉。\n这些年国内CXO众神的飞速发展得益于这几个因素：一、工程师红利。我国本硕博供给井喷且劳动力成本相对较低（只相当于欧美国家的30%-50%），加上这几年海外相关领域的领军人才回国创业，两相结合，优势凸显。\n二、前几年中国医药外包市场的渗透率较低，2018年才35%左右。\n三、国际医药研发外包服务的产业转移，但从目前不断增长的各种成本来看，未来的产业转移速度要打个疑问了。\n四、近几年资本给国内创新药公司的疯狂投入。\n其他基本面就不用细谈了，我们来看看未来的发展潜力吧。\n01\nCXO的增长是与创新药公司的增长息息相关的，要判断CXO的黄金周期必定离不开创新药的发展增长周期。\n从国外成熟市场来看，在研药物规模增速和CXO增速是相匹配的，我们来看看全球和中国的医药市场规模：\n2016年全球医药市场规模为11536亿美元，预计将在2021年达到14751亿美元，复合增速约5%。\n从地域来看，美国仍是世界上最大的医药市场，2016年美国市场规模约占同期全球市场38%的份额。而中国作为全球最大的新兴市场，近年随需求不断提升，其市场规模也保持高速增长，预计到2021年将达到1782亿美元，增速约8%。\n再来看看这几年国内生物科技公司的融资情况，融资的高点与医药外包增长高点应该是前后相关性很明显的。下图可以看到2019、2020年是融资的高峰期，融资高峰后的两年也应该是CXO赛道增长的高峰。目测下图2020年、2021年会是国内CXO业绩增长的高峰。再来看看医药市场发展的同时医药外包服务起到的作用有多大，目前国外医药研发外包的渗透率已达到55%左右，而国内的医药研发外包渗透率仍在40%到45%左右。\n也就是如果没有国外市场，那么未来国内医药外包还有10到15%的潜力可以挖掘。\n从医药研发外包发展的实际渗透率和预计来看，增长是超预期的。未来发展的天花板应该很低了，有行业人士预测渗透率天花板在60%到65%左右甚至更低。补充一张国内医药外包渗透率的图片，我觉得根据其他数据综合来看有点低估了。国外的医药外包市场已经非常成熟了，相比国内而言赛道增长速度是放低很多，从权威的数据来看，一个成熟的市场的CXO增长速度大概10%左右。\n02\n全球医药外包市场规模超千亿美元，其中化药C(D)MO市场规模占比最大，生物药C(D)MO增速最快。据悉，2013—2017年年均复合增长率10.3%，全球医药外包市场规模整体增长平稳。\n2017年总体市场规模达到1041亿美元，其中CRO市场规模446亿美元，占43%，C(D)MO市场规模595亿美元，占57%。\n未来5年，全球CRO+C(D)MO行业仍将保持高速增长，2022年全球医药外包行业规模将达1784亿美元，年均复合增长率达11.4%。中国的医药外包规模预计增长情况如下，大概年均增长率12%左右。再多说一句，如果从CXO的细分行业来看，有两个方面值得大家注意：一是CRO企业不管是以前还是未来的发展趋势都远不及CDMO企业；二是主要收入来源于国际的CXO企业未来竞争力远大于国际收入占比低的企业。\n这里就不展开细说了。下面图片给大家参考。综上来看，全球医药市场包括中国市场主要有两个主要因素决定了CXO赛道未来的增长情况：一是医药市场的规模增长，特别是创新药发展的增速；二是医药外包市场的渗透率增长。全球医药市场增长预期是5%，中国是8%，目前的渗透率，全球55%，中国是40%到45%左右。 聊到了这里，结论已经不言而喻了。\n除了头部几个一线的最优质的CXO企业，其他的大家且行且珍重。","news_type":1,"symbols_score_info":{"WX":0.9}},"isVote":1,"tweetType":1,"viewCount":1687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122309831,"gmtCreate":1624595682423,"gmtModify":1703841324350,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586297136997911","idStr":"3586297136997911"},"themes":[],"htmlText":"look&nbsp;","listText":"look&nbsp;","text":"look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122309831","repostId":"1102925117","repostType":4,"repost":{"id":"1102925117","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624582814,"share":"https://ttm.financial/m/news/1102925117?lang=en_US&edition=fundamental","pubTime":"2021-06-25 09:00","market":"hk","language":"zh","title":"XPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39","url":"https://stock-news.laohu8.com/highlight/detail?id=1102925117","media":"老虎资讯综合","summary":"6月25日，小鹏汽车-W发布公告，公司于6月25日至6月30日招股；拟全球发售8500万股股份，其中香港发售股份425万股，国际发售股份8075万股，另有15%超额配股权；每股发行价不超过180港元，","content":"<p>June 25th,<a href=\"https://laohu8.com/S/09868\">XPeng Motor-W</a>Announced that the company will issue an IPO from June 25th to June 30th; It plans to sell 85 million shares globally, including 4.25 million shares offered in Hong Kong, 80.75 million shares offered internationally, and a 15% over-allotment option; The issue price per share does not exceed HK $180, each lot of trading unit is 100 shares, and the admission fee is about HK $18,181.39; The Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/1e2905fbe978b70a1fadc57bfb9804ec\" tg-width=\"891\" tg-height=\"622\" referrerpolicy=\"no-referrer\"></p><p>Subscription ladder:</p><p>There are 100 shares per lot, and the admission fee is HK $18,181.39.</p><p>The threshold for Group B is 30,000 shares, and the funds required for subscription are approximately HK $5,454,415.8.</p><p><img src=\"https://static.tigerbbs.com/a8dafe8d708afb61e06e25e0b275bf27\" tg-width=\"934\" tg-height=\"360\" referrerpolicy=\"no-referrer\"></p><p>Founded in 2015, XPeng Motors has developed into the country's leading smart electric vehicle company, listed on the New York Stock Exchange in August 2020. XPeng Motor is engaged in the design, research and development, manufacturing and marketing of smart electric vehicles in the PRC. According to IHS Markit, as of the Latest Practicable Date, the company is the only automobile company in China that independently develops full-stack autonomous driving technology and applies the software to mass-produced vehicles. The company is building a rapidly expanding and diversified portfolio of attractive smart electric vehicle models to meet the growing demand for smart electric vehicles and the differentiated needs of its broad customer base.</p><p>As of 2021Q1, XPeng Automobile has 178 sales stores and 61 service centers nationwide, covering 70 cities, and most of the stores are located in shopping malls. In terms of charging facility network layout, as of 2021Q1, there are 172 XPeng brand super charging stations across the country, covering 60 cities. The company offers a free charging plan to eligible car owners, and by the end of March, the plan has covered more than 140 cities.</p><p>In terms of financial data, the company achieved significant growth and strong operating results during the Track Record Period. From 2018 to 2020, the company's total revenue increased from 9.706 million yuan to 5.844 billion yuan. With strong revenue growth, the company's gross profit margin increased from (24.3%) in 2018 to 4.6% in 2020, turning positive. In the first quarter of 2021, the company recorded total revenue of 450 million yuan, net loss of 120 million yuan, and gross profit margin of 11.2%.</p><p><img src=\"https://static.tigerbbs.com/853e033a96dad5cd098377abcd2fede8\" tg-width=\"973\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>In terms of fund-raising purposes, based on the upper limit of the offer price of HK $180, the IPO is expected to receive net proceeds of approximately HK $15.039 billion from the global offering (after deducting underwriting commissions and other estimated expenses related to the global offering). The company intends to use the net proceeds from the share offer for the following purposes: approximately 45% is expected to be used to expand the company's product portfolio and develop more advanced technologies; About 35% is expected to be used to accelerate the company's business expansion by enhancing the company's brand awareness, acquiring customers through omni-channel marketing strategies, and increasing sales and service coverage in domestic and international markets; Approximately 10% is expected to be used to improve production capacity, including expanding production capacity, upgrading production facilities and developing production technology; Approximately 10% is expected to be used for general corporate purposes, including working capital.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-25 09:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>June 25th,<a href=\"https://laohu8.com/S/09868\">XPeng Motor-W</a>Announced that the company will issue an IPO from June 25th to June 30th; It plans to sell 85 million shares globally, including 4.25 million shares offered in Hong Kong, 80.75 million shares offered internationally, and a 15% over-allotment option; The issue price per share does not exceed HK $180, each lot of trading unit is 100 shares, and the admission fee is about HK $18,181.39; The Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/1e2905fbe978b70a1fadc57bfb9804ec\" tg-width=\"891\" tg-height=\"622\" referrerpolicy=\"no-referrer\"></p><p>Subscription ladder:</p><p>There are 100 shares per lot, and the admission fee is HK $18,181.39.</p><p>The threshold for Group B is 30,000 shares, and the funds required for subscription are approximately HK $5,454,415.8.</p><p><img src=\"https://static.tigerbbs.com/a8dafe8d708afb61e06e25e0b275bf27\" tg-width=\"934\" tg-height=\"360\" referrerpolicy=\"no-referrer\"></p><p>Founded in 2015, XPeng Motors has developed into the country's leading smart electric vehicle company, listed on the New York Stock Exchange in August 2020. XPeng Motor is engaged in the design, research and development, manufacturing and marketing of smart electric vehicles in the PRC. According to IHS Markit, as of the Latest Practicable Date, the company is the only automobile company in China that independently develops full-stack autonomous driving technology and applies the software to mass-produced vehicles. The company is building a rapidly expanding and diversified portfolio of attractive smart electric vehicle models to meet the growing demand for smart electric vehicles and the differentiated needs of its broad customer base.</p><p>As of 2021Q1, XPeng Automobile has 178 sales stores and 61 service centers nationwide, covering 70 cities, and most of the stores are located in shopping malls. In terms of charging facility network layout, as of 2021Q1, there are 172 XPeng brand super charging stations across the country, covering 60 cities. The company offers a free charging plan to eligible car owners, and by the end of March, the plan has covered more than 140 cities.</p><p>In terms of financial data, the company achieved significant growth and strong operating results during the Track Record Period. From 2018 to 2020, the company's total revenue increased from 9.706 million yuan to 5.844 billion yuan. With strong revenue growth, the company's gross profit margin increased from (24.3%) in 2018 to 4.6% in 2020, turning positive. In the first quarter of 2021, the company recorded total revenue of 450 million yuan, net loss of 120 million yuan, and gross profit margin of 11.2%.</p><p><img src=\"https://static.tigerbbs.com/853e033a96dad5cd098377abcd2fede8\" tg-width=\"973\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>In terms of fund-raising purposes, based on the upper limit of the offer price of HK $180, the IPO is expected to receive net proceeds of approximately HK $15.039 billion from the global offering (after deducting underwriting commissions and other estimated expenses related to the global offering). The company intends to use the net proceeds from the share offer for the following purposes: approximately 45% is expected to be used to expand the company's product portfolio and develop more advanced technologies; About 35% is expected to be used to accelerate the company's business expansion by enhancing the company's brand awareness, acquiring customers through omni-channel marketing strategies, and increasing sales and service coverage in domestic and international markets; Approximately 10% is expected to be used to improve production capacity, including expanding production capacity, upgrading production facilities and developing production technology; Approximately 10% is expected to be used for general corporate purposes, including working capital.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8a7cf240033f083a329240e6179df017","relate_stocks":{"09868":"小鹏汽车-W","XPEV":"小鹏汽车"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102925117","content_text":"6月25日，小鹏汽车-W发布公告，公司于6月25日至6月30日招股；拟全球发售8500万股股份，其中香港发售股份425万股，国际发售股份8075万股，另有15%超额配股权；每股发行价不超过180港元，每手买卖单位100股，入场费约18181.39港元；预期股份将于7月7日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手100股，入场费18181.39港元。\n乙组门槛为3万股，申购所需资金约5454415.8港元。\n\n小鹏汽车成立于2015年，目前已发展成中国领先的智能电动汽车公司，于2020年8月在纽交所上市。小鹏汽车在中国从事智能电动汽车的设计、研发、制造及营销。根据IHS Markit的数据，截至最后实际可行日期，公司是中国唯一一家自主开发全栈式自动驾驶技术，并在量产汽车上应用该软件的汽车公司。公司正在打造一个快速扩展、多元化的具有吸引力的智能电动汽车车型组合，以满足智能电动汽车日益增长的需求以及广大客户群的差异化需求。\n截至2021Q1，小鹏汽车全国销售门店达178家，服务中心达61家，覆盖70个城市，绝大多数门店均位于购物中心。充电设施网络布局方面，截至2021Q1，全国共有172座小鹏品牌超级充电站，覆盖60个城市。公司向符合条件的车主提供免费充电计划，截至3月底，该计划已覆盖超过140个城市。\n财务数据方面，于往绩记录期间，公司实现了显著的增长及强劲的经营业绩。2018年至2020年，公司总收入由970.6万元增长至58.44亿元。随着收入的强劲增长，公司毛利率从2018年的(24.3%)增长至2020年的4.6%，实现转正。2021年一季度，公司录得总收入4.50亿元，净亏损1.20亿元，毛利率达到11.2%。\n\n筹资用途方面，以发售价的上限180港元计算，此次IPO预计自全球发售收取所得款项净额约150.39亿港元（经扣除包销佣金及与全球发售有关的其他估计开支）。公司拟将股份发售所得款项净额用于以下用途：约45%预期将用于拓展公司的产品组合及开发更先进的技术；约35%预期将用于通过提升公司的品牌认知度，借助全渠道营销策略获取客户，以及在国内及国际市场增加销售及服务覆盖，来加速公司的业务扩张；约10%预期将用于提升生产能力，包括扩大产能、升级生产设施和开发生产技术；约10%预期将用于一般公司用途，包括用作运营资金。","news_type":1,"symbols_score_info":{"XPEV":0.9,"09868":0.9}},"isVote":1,"tweetType":1,"viewCount":1594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163854576,"gmtCreate":1623876777695,"gmtModify":1703822108690,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586297136997911","idStr":"3586297136997911"},"themes":[],"htmlText":"up","listText":"up","text":"up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163854576","repostId":"1174117014","repostType":4,"repost":{"id":"1174117014","kind":"news","weMediaInfo":{"introduction":"关注中国基金报，即时获取深度理财资讯","home_visible":1,"media_name":"中国基金报","id":"6","head_image":"https://static.tigerbbs.com/2b2c79a68beb44c7bc06ad7210091200"},"pubTimestamp":1623850133,"share":"https://ttm.financial/m/news/1174117014?lang=en_US&edition=fundamental","pubTime":"2021-06-16 21:28","market":"sh","language":"zh","title":"Funds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1174117014","media":"中国基金报","summary":"A股有上演“跳水”的节奏，上证指数、沪深300、深证成指分别下跌1.07%、1.67%、2.57%，创业板指更是一口气下跌4.18%。\n在这一背景下，“基金走势”又登上热搜，不少投资者在微博上讨论基金","content":"<p><div>A-shares have a \"diving\" rhythm. The Shanghai Composite Index, CSI 300, and Shenzhen Component Index fell by 1.07%, 1.67%, and 2.57% respectively, and the ChiNext Index fell by 4.18% in one go. Against this background, \"fund trend\" has become a hot search topic again, and many investors discussed the trend of fund net value on Weibo, which caused heated discussions. However, opportunities often arise amid market fluctuations. Fund Jun integrates Nanfang, Bosera, Harvest, China Merchants, China Europe, ICBC Credit Suisse, Cathay Pacific, Chuangjin Hexin, HSBC Jintrust, Nord, Debon, Yongying, Essence, Golden Eagle, Qianhai Kaiyuan and other 15 fund companies' market outlook views found that many...</p><p><a href=\"None\">Web link</a></div></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Funds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFunds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/6\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/2b2c79a68beb44c7bc06ad7210091200);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">中国基金报 </p>\n<p class=\"h-time smaller\">2021-06-16 21:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><div>A-shares have a \"diving\" rhythm. The Shanghai Composite Index, CSI 300, and Shenzhen Component Index fell by 1.07%, 1.67%, and 2.57% respectively, and the ChiNext Index fell by 4.18% in one go. Against this background, \"fund trend\" has become a hot search topic again, and many investors discussed the trend of fund net value on Weibo, which caused heated discussions. However, opportunities often arise amid market fluctuations. Fund Jun integrates Nanfang, Bosera, Harvest, China Merchants, China Europe, ICBC Credit Suisse, Cathay Pacific, Chuangjin Hexin, HSBC Jintrust, Nord, Debon, Yongying, Essence, Golden Eagle, Qianhai Kaiyuan and other 15 fund companies' market outlook views found that many...</p><p><a href=\"None\">Web link</a></div></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"159915":"创业板","399006":"创业板指","000001.SH":"上证指数"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174117014","content_text":"A股有上演“跳水”的节奏，上证指数、沪深300、深证成指分别下跌1.07%、1.67%、2.57%，创业板指更是一口气下跌4.18%。\n在这一背景下，“基金走势”又登上热搜，不少投资者在微博上讨论基金净值走势引发热议。\n\n然而机遇往往在市场波动中出现，基金君综合南方、博时、嘉实、招商、中欧、工银瑞信、国泰、创金合信、汇丰晋信、诺德、德邦、永赢、安信、金鹰、前海开源等15家基金公司后市观点发现，多家基金公司认为调整直接诱因是晚间美联储将再次召开利率会议，市场对于未来一段时间美联储货币政策收紧的预期 逐步达成共识，因此这一调整体现出当前资金整体避险情绪浓厚。\n不过，不少人士认为市场调整不改大市场大趋势，也给市场布局机遇，2021年市场存在结构性机遇，比较看好科技、新能源、周期、消费、金融等。\n多因素引发市场调整\n究竟是什么引发了6月16日的市场大跌？不少人士提及美联储将再次召开利率会议，这引起市场担忧美联储货币政策收紧，叠加前期市场上涨带来的内在调整要求，引发了今日市场大跌。\n中欧基金表示，今日晚间美联储将再次召开利率会议，市场对于未来一段时间美联储货币政策收紧的预期 逐步达成共识，但紧缩幅度仍存在一定分歧，在此情形下，今日市场大幅调整体现出当前资金整体避险情绪浓厚。\n在近期指数窄幅震荡的情况下，主题板块表现十分活跃，市场成交也处于高位，显示部分活跃资金在不断寻找突破的方向，但在权重保持稳定的情形下，更多的表现出“打游击”的典型特征，个股震荡幅度显著增大，连续上涨的可能性较小。\n而国泰基金也认为，今天市场调整的主要原因在于市场对美联储Taper（逐渐缩减资产购买规模）的担忧。美联储议息会议临近，由于担忧美联储对Taper发表鹰派表态，投资者情绪受到影响，引发市场下跌。而前期市场涨幅较高的新能源车、光伏等行业首当其冲，回调显著；银行等低估值行业避险。\n博时基金表示，今日A股大幅下行，主要是由于维稳时间窗口期越来越窄、A股性价比较差、对负面消息敏感度提升所致。美国昨日公布的PPI和零售销售数据、以及正在召开的美联储会议，或也对市场造成了一定的扰动。\n年初以来，国内经济基本面维持良好的修复动能，工业生产和出口均维持较高的景气度，目前全球的通胀水平继续上行，我国的货币政策依然以稳健为主，流动性相对温和。未来A股或仍以震荡为主，市场风格或将更趋于均衡。在中国新经济结构背景下，未来或仍以结构性机会为主，部分板块和个股经过前期的调整，估值或已进入相对合理的区间，可适当关注性价比高的绩优股的机会。\n南方基金认为，整体来看，市场自三月底以来呈现回暖反弹的状态，光伏新能源、生物医药等行业不少个股已收复前期跌幅，甚至创下新高。进入六月份，部分资金在价格到达前高后选择获利了结，个股层面的博弈性质明显增加。与此同时，我们看到市场成交量在万亿水平维持了数日，反映出资金对于后市存在较大分歧。归其原因，主要是市场缺乏投资主线。因此才有了结构的快速轮动以及部分题材的持续炒作。\n招商基金表示，近期市场题材轮动加快，前期持续上涨的板块出现高位回落；指数方面连续走弱，权重板块无明显主动护盘动作，短期市场风险仍有待进一步释放。今日市场出现较为明显的调整，前期强势的电车、医药、周期调整幅度较大。调整的原因主要是前期部分板块涨幅较大、市场获利了结心理较重，而阶段性的流动性宽松程度已难以进一步加码，同时叠加美联储议息会议在即，海外不确定性有所增加。\n嘉实基金表示，第一、创业板从3月25日到6月15日，上涨23.8%，反弹幅度较大 ，本身有整固需要。第二、美国5月数据超预期，CPI同比增5%，PPI同比增6.6%，通胀预期强烈，市场对流动性有所担忧。第三、美国零售额同比下降，或降低美联储会议鹰派决策的可能性，最终美联储会议结果，会在北京时间明日凌晨发布，今日部分避险资金提前流出。不过，截至6月16日收盘，上证指数PE为14.1，处于历史相对低位，长期投资价值凸显。嘉实基金维持2021年结构性机会丰富的判断，相对看好消费、科技板块里的成长型中小市值公司，以及低估值的金融等顺周期板块。\n工银瑞信表示，今日市场下跌主要受市场担忧美联储议息会议结果、国家粮食和物资储备局分批投放铜铝锌等国家储备等因素的影响。明天凌晨将会公布美联储议息会议结果，市场担忧美联储出现“鹰派”表述。前期涨幅较多的新能源车、光伏、医药等行业明显回调。国家粮食和物资储备局公告，按照国务院常务会议关于做好大宗商品保供稳价工作部署，将于近期分批投放铜、铝、锌等国家储备。投放面向有色金属加工制造企业，实行公开竞价，相关工作由国家物资储备调节中心具体负责。\n虽然经济改善最快的阶段可能已经过去，但在PPI高位缓慢回落背景下盈利仍有一定支撑，全年A股盈利增速整体还将处于改善通道中。当前货币政策仍强调稳字当头，尚未出现明显转向，但政策在稳杠杆、控风险上的权重逐步加大，预计货币政策仍将延续信用端结构性收紧、货币端维持平稳的态势。当前主要指数估值水平处于历史相对高位，预计短期指数将维持震荡格局，以结构性机会为主。风险方面，关注海外疫情、美股波动性加大等海外不确定性。\n创金合信基金首席策略分析师、首席投资官助理王婧认为，今日两市集体下跌，前期热门板块医药、白酒、新能源、汽车等均出现较大幅度的回调。下跌的主要原因还是来自市场的内在调整要求。一季度市场出现较大波动，在3月下旬进入筑底期，并展开反弹。创业板作为反弹的主要领导指数，在四、五月已经积累了20%的涨幅，短期上涨过快后，调整也是必然现象。特别是接近前期高点附近，市场出现震荡整固，放慢上涨节奏也符合预期。部分市场参与者对七一之后行情的稳定性存在担忧，提前获利了结也是加大市场波动的原因之一。\n从经济环境来看，一季度美债利率超预期上涨，海外市场大幅波动传导至国内资产价格的风险再现的可能不大。尽管美国通胀超预期，但美债利率已回落至1.5%左右，美国流动性非常宽裕。美元流动性外溢推动人民币汇率持续走高，国内十年期国债利率中枢下移，国内资产价格大幅下行的风险不大。盈利方面，A股今年仍有结构性亮点，医药、消费、新能源、科技等细分行业中不乏高景气高成长性的赛道和品种，在整体市场增量资金不多，但总量仍属充裕的环境下，这些领域仍会持续创造超额收益。\n安信基金表示，受美联储政策会议即将召开影响，今日市场较为谨慎。从外部看，一方面，本周全球迎来“超级央行周”，而美国公布的5月CPI同比升5%，创2008年8月来新高。通胀压力较大的情况下，市场高度关注周四凌晨美联储FOMC公布的利率决议、政策声明及经济预期的内容，市场情绪趋于谨慎，隔夜美股也出现调整，提升A股避险情绪。目前市场普遍预计美联储将在此次决议上按兵不动。美联储可能会在8月或9月宣布缩减计划，并在明年初开始执行。\n从A股来看，A股前期出现了一轮强反弹行情，而近期美元指数在90附近企稳之后，汇率升值影响有所弱化。目前市场普遍谨慎，前期各大热点的热度均有所下降。蓄势等待、立足业绩和估值的匹配度，关注中报业绩是短中期的主要思路。\n诺德基金顾钰也认为市场下跌原因是近期部分行业上涨过快，属于正常回调。\n德邦基金直言，今日市场大跌，主要由于之前高风险偏好资金倾向于提前兑现，而且当前资金面略偏紧，也压制了风险偏好。海外方面，今日晚间将召开美联储议息会议，市场对Taper（收紧）也并无特别担忧，纳斯达克、英法德等指数都是新高状态。无论是基本面，还是消息层面，并无特别风险点，倾向于认为当前更多是风险偏好的扰动，后续深跌的可能性不大，市场风格或将重回成长，围绕行业景气度继续震荡上行。\n震荡不改市场中期趋势\n谈及近期市场，不少人士认为从全年维度看，市场仍存在结构性的做多机会，会维持震荡格局。\n南方基金表示，宏观流动性收紧与盈利基本面向上是今年两大主线。前者会挤压资金的风险偏好，进而对市场估值形成一定压制，而后者确保了市场的质地和韧性。同时，社会不同经济部门受疫情影响的程度存在较大差异，行业间景气分化明显。因此，政策全面收紧的概率不大，所以权益市场发生系统性风险的可能性低。\n中短期而言，市场会维持震荡格局，出现趋势性大涨大跌的概率不大，主要原因是当前市场整体情绪不算亢奋，部分结构表现出的过热现象会通过一定的轮动来消化。同时，资金端仍较为宽松，流动性环境并不差。中长期而言，我们继续保持乐观态度，国内股市运行中枢逐年抬升的趋势非常明显，医药消费科技是长期布局的主赛道。\n中欧基金表示，中国当前已步入由繁荣转向过热的经济阶段，预计地产和基建等传统投资端将逐渐向中长期趋势回归，增速环比下行。在此情境下对内需依赖度较高的周期行业后续的业绩爆发力 可能较海外偏弱，而新经济的盈利周期尚未大幅开启，市场预期较高时价格往往出现较大波动；国内政策回归正常化的趋势和经济增长环比趋缓的背景之下，全市场整体估值难有提升，此时应适当放低回报预期，而细分机会将来自高成长性带来的业绩增长。\n招商基金展望后市认为，从全年维度看，在国内外经济持续修复、通胀压力仍存的背景下政策回撤的方向仍较为明确，但考虑到国内外整体货币政策基调并未进一步收紧，且全球经济复苏前景良好，市场仍存在结构性的做多机会。继续关注宏观经济深度复苏，景气度改善的低估值顺周期品种如银行和上游资源股的修复机会；对于新能源、白酒等近期涨幅较大的高景气行业，仍需对于估值和基本面景气度的匹配程度给予更高的筛选要求；中长期资金可在回落企稳后布局中报高增长、估值相对合理的细分方向。\n上述诺德基金顾钰表示，对于未来市场，依旧持谨慎乐观的看法。当前各国纷纷进入疫苗注射阶段，同时部分国家也出现疫情的爆发，我国少数城市也出现疫情但相对可控，属于疫苗和疫情赛跑的后疫情时代。全球经济正在从疫情中恢复，企业盈利改善从数据中持续得到确认。但经济恢复还需一个过程，因此流动性短时间内快速收紧的概率也很小。在春节后的一轮市场调整之后，高估值的压力有所释放，基本面优秀并且业绩确定性和持续性强的优质公司有望是市场重点配置方向。\n从中长期来看，我国金融开放的力度加大，外资持续流入的趋势不变。国内房住不炒的思路延续，叠加理财产品打破刚兑，权益市场有望承接居民资产配置的需求。从结构上看，中长期看好景气度向上的方向如白酒为代表的大消费、医药、新能源汽车等。\n国泰基金展望未来表示，A股中性偏多、宽幅震荡的格局没有变化，出现单边熊市的概率相对较低。从宏观经济看，地产韧性较强，基建维稳，制造业持续恢复。出口方面，在全球疫情后复苏阶段，预计下半年出口仍将保持韧性，PPI增速预计在三季度保持高位，四季度小幅回落。流动性层面，社融增速预计在三季度企稳，货币政策将维持中性。基本面方面，今年中报和下半年A股基本面大概率会稳健向上，企业的盈利能力和成长性将成为下一阶段市场的核心逻辑。\n而永赢基金展望未来表示，短期而言本周重点关注美联储议息会议。结构上，在经济动能减弱叠加流动性宽松的环境中，短期市场重新寻求确定性，高景气品种是重要配置方向，也是内外资的共识，以新能源产业链和白酒为代表的业绩确定性较强的核心资产股表现靠前。另外，在流动性宽松的环境下，受益于“鸿蒙”概念相关的计算机和电子等成长板块可能也有阶段性机会。\n从中期来看，克制基于总量变化布局的冲动，可以利用震荡格局优化持仓结构。市场总体反弹延续还需要一些催化剂，比如紧缩预期消退、甚至是宽松预期发酵的配合，这或许很难出现。主要是3月以来资金宽松的逻辑很难持续，一方面财政节奏偏慢的因素可能在下半年有所改变，随着债券发行速度加快，市场利率上行压力加剧；另一方面，也与美元流动性宽松外溢的被动因素相关，下半年随着美国经济加速修复将支撑美元指数上行。因此，需要克制基于总量变化布局的冲动，可以利用震荡格局优化持仓结构，结构上挑选基本面改善较强以及2021年业绩确定性较强的板块及个股。\n金鹰基金表示，整体来看，今日市场回调主要反映对国内外流动性的担忧，风偏回落下资金选择落袋为安。展望后市，预计A股仍将保持高位震荡，下行空间有限。我们预计，央行仍将维持“稳货币、紧信用”的基调，国内流动性并未大幅度转向，投资者在等待美联储动向的进一步明朗。而在中报业绩的加持下，A股并不具备持续回调的动力。\n前海开源首席经济学家杨德龙表示，A股市场经过前一轮的大幅下跌之后出现了一轮反弹，前段时间市场的情绪一度上升，但结构性行情的特征依然是非常明显的，建议逢低布局的像白酒、中药、光伏、新能源汽车等行业的龙头股大幅上涨，个别白龙马股甚至创出历史新高，形成了比较强的赚钱效应。可以说每轮大跌都是抄底优质股票的时机，概莫能外。\n市场短期的调整主要是反映对于美联储货币政策可能变化的一种预期。一旦美联储议息会议结束，周四公布议息会议的结果是不会加息，继续保持当前宽松政策的话，A股可能会出现强劲回升。市场短期的走势主要是由投资者的情绪所决定，和基本面并没有太大的联系，而长期来看，做价值投资，做好公司的股东，才能够从长期获得好的回报。\n主要看好新能源、消费品等\n中欧基金表示，成长股整体仍显著高于价值股的估值水平，而在偏高估值压力之下，成长股的成长确定性较成长性更加重要，随着上半年业绩的逐步落地，此时依然可以关注业绩确定性较高的新 能源、智能车、医疗服务等行业回调时的投资机会。此外，海外经济复苏仍在驱动大宗商 品价格上涨，虽然国内周期品上行推动力在投资端增速预计环比收敛和政策干预之下或将 逐渐减弱，但周期行业中下游需求偏重外需的行业如化工和航运等预计仍具备一定空间。\n国泰基金表示，仍然看好科技与新能源、周期金融、必须消费。“稳货币、紧信用”阶段，具备产业逻辑驱动的成长股仍可以占优，关注碳中和长期受益的光伏、新能源车。尽管短期有所调整，但是市场流动性预期的改变并不改变基本面的事实，它们代表的是经济转型发展方向，基本面并未发生变化。此外，我们还关注周期金融板块中的电解铝、铜、银行；必选消费中，医药相对占优。\n对于基金投资来说，如果长期看好新能源板块，则不妨在市场阶段性调整的阶段低位布局；如果担忧市场震荡，也可以选择追求稳健收益的“固收+”类产品。\n汇丰晋信首席宏观及策略师闵良超认为，对于后市，我们依然看好新能源汽车产业链、以化工为代表的一部分周期行业、军工的一些细分子行业、以及大金融板块的投资机会。不过我们始终认为，今年市场不太可能出现类似2019、2020年这样的系统性行情，市场整体表现会更加均衡，也需要我们自下而上不断地去衡量基本面和估值的变化，动态地挖掘市场机会。\n永赢基金则关注三大方向，第一是沿着外需复苏关注服务、海外地产投资端以及耐用品的中间品等，内需关注服务、消费品（特别是兼顾价格传导能力，白酒汽车家电）、地产后周期（建材、轻工）、制造业投资（机械）；\n第二、一季报验证高景气的方向：电气设备（新能源汽车）、医药生物（医疗服务高增速的持续性更好）和电子（半导体和被动元件），可以选择性价比较高的细分板块；\n第三、重视未来5年的大主题碳中和对各行各业的影响，清洁能源、钢铁、电解铝、水泥玻璃等高耗能产业的影响深远。","news_type":1,"symbols_score_info":{"159915":0.9,"399006":0.9,"000001.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183868518,"gmtCreate":1623322455934,"gmtModify":1704200848771,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586297136997911","idStr":"3586297136997911"},"themes":[],"htmlText":"hi ,nice to meet here","listText":"hi ,nice to meet here","text":"hi ,nice to meet here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183868518","isVote":1,"tweetType":1,"viewCount":1323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":159938617,"gmtCreate":1624934785339,"gmtModify":1703848316585,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586297136997911","authorIdStr":"3586297136997911"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/159938617","repostId":"1104770632","repostType":4,"isVote":1,"tweetType":1,"viewCount":1643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122303537,"gmtCreate":1624595733929,"gmtModify":1703841326454,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586297136997911","authorIdStr":"3586297136997911"},"themes":[],"htmlText":"oh","listText":"oh","text":"oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122303537","repostId":"1198330093","repostType":4,"repost":{"id":"1198330093","kind":"news","weMediaInfo":{"introduction":"民间投资共享平台——汇集投资高手，发现投资好点子。","home_visible":1,"media_name":"阿尔法工场研究院","id":"1026500124","head_image":"https://static.tigerbbs.com/4df70e92a2d64be896797ea06b5e676a"},"pubTimestamp":1624588229,"share":"https://ttm.financial/m/news/1198330093?lang=en_US&edition=fundamental","pubTime":"2021-06-25 10:30","market":"sh","language":"zh","title":"A brief discussion on the valuation bubble of CXO track","url":"https://stock-news.laohu8.com/highlight/detail?id=1198330093","media":"阿尔法工场研究院","summary":"随着CXO渗透率的提高，未来行业增速将快速下降。\n聊之前，先说结论：目前无论你持有哪一只CXO股票，现在的一两百的pe，估值明显都已经是泡沫了，但泡沫不意味着要你止盈，只是要给大家提个醒，对未来期望有","content":"<p><img src=\"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29\" tg-width=\"1080\" tg-height=\"721\" referrerpolicy=\"no-referrer\"><b>As the penetration rate of CXO increases, the growth rate of the industry will decline rapidly in the future.</b></p><p>Before chatting, let's talk about the conclusion: No matter which CXO stock you hold at present, the current pe of one or two hundred, the valuation is obviously a bubble, but the bubble does not mean that you need to take profits, but just to remind everyone. Wake up, have correct psychological expectations for future expectations.</p><p>The CXO track has undoubtedly been one of the highest quality tracks in A-shares in recent years, and one of these can even be removed.</p><p>The rapid development of domestic CXO gods in recent years has benefited from these factors: First, engineer dividends. The supply of undergraduate, master's and doctoral degrees in China is blowout and the labor cost is relatively low (only equivalent to 30%-50% of that in European and American countries). In addition, in recent years, leading talents in overseas related fields have returned to China to start businesses. The combination of the two has outstanding advantages.</p><p>2. The penetration rate of China's pharmaceutical outsourcing market was low in the past few years, and it was only about 35% in 2018.</p><p>3. Industrial transfer of international pharmaceutical R&D outsourcing services, but judging from the current increasing costs, the future speed of industrial transfer needs to be questioned.</p><p>4. In recent years, capital has invested crazily in domestic innovative drug companies.</p><p>There is no need to talk about other fundamentals in detail. Let's take a look at the future development potential.</p><p><b>01</b></p><p>The growth of CXO is closely related to the growth of innovative drug companies.<b>To judge the golden cycle of CXO, it must be inseparable from the development and growth cycle of innovative drugs.</b></p><p>From the perspective of mature foreign markets, the growth rate of drugs under development matches the growth rate of CXO. Let's take a look at the global and Chinese pharmaceutical market size:</p><p><img src=\"https://static.tigerbbs.com/97773744b4b5641959840aaa0410f500\" tg-width=\"516\" tg-height=\"348\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7b8157b70922b8885798ae8bec9850cf\" tg-width=\"514\" tg-height=\"341\" referrerpolicy=\"no-referrer\">The global pharmaceutical market size in 2016 was US $1,153.6 billion, and is expected to reach US $1,475.1 billion in 2021, with a compound growth rate of approximately 5%.</p><p>From a geographical point of view, the United States is still the largest pharmaceutical market in the world. In 2016, the US market accounted for approximately 38% of the global market during the same period. As the world's largest emerging market, China's market size has maintained rapid growth in recent years as demand has continued to increase. It is expected to reach US $178.2 billion by 2021, with a growth rate of about 8%.</p><p>Let's take a look at the financing situation of domestic biotechnology companies in recent years. The high point of financing and the high point of pharmaceutical outsourcing growth should be obviously correlated. As you can see from the figure below, 2019 and 2020 are the peak periods of financing, and the two years after the peak of financing should also be the peak of CXO track growth.<img src=\"https://static.tigerbbs.com/77382e31cfaea57bcbe2a6d0e0fd118c\" tg-width=\"506\" tg-height=\"349\" referrerpolicy=\"no-referrer\">Visually, 2020 and 2021 in the figure below will be the peak of domestic CXO performance growth.<img src=\"https://static.tigerbbs.com/9abb7b6623e38f03db5ab2fe4ec70af3\" tg-width=\"516\" tg-height=\"354\" referrerpolicy=\"no-referrer\">Let's take a look at the role of pharmaceutical outsourcing services while the pharmaceutical market is developing. At present, the penetration rate of foreign pharmaceutical R&D outsourcing has reached about 55%, while the penetration rate of domestic pharmaceutical R&D outsourcing is still around 40% to 45%.</p><p>That is to say, if there is no foreign market, then there is still 10 to 15% potential for domestic pharmaceutical outsourcing to be tapped in the future.</p><p>Judging from the actual penetration rate and expectations of pharmaceutical R&D outsourcing development, the growth exceeded expectations.<b>The ceiling for future development should be very low.</b>Some industry insiders predict that the penetration rate ceiling will be around 60% to 65% or even lower.<img src=\"https://static.tigerbbs.com/242f24b01dd6070eb041e944988dc3df\" tg-width=\"558\" tg-height=\"351\" referrerpolicy=\"no-referrer\">To add a picture of the penetration rate of domestic pharmaceutical outsourcing, I think it is a bit underestimated based on other data.<img src=\"https://static.tigerbbs.com/0b764f34f3aad9e995adfc0b88e3b44c\" tg-width=\"649\" tg-height=\"454\" referrerpolicy=\"no-referrer\"><b>The foreign pharmaceutical outsourcing market is already very mature. Compared with the domestic market, the growth rate of the track is much lower. According to authoritative data, the growth rate of CXO in a mature market is about 10%.</b></p><p><b>02</b></p><p>The global pharmaceutical outsourcing market exceeds US $100 billion, of which the chemical drug C (D) MO market accounts for the largest share, and the biological drug C (D) MO has the fastest growth rate. It is reported that the average annual compound growth rate from 2013 to 2017 is 10.3%, and the overall growth of the global pharmaceutical outsourcing market is steady.</p><p>The overall market size reached US $104.1 billion in 2017, of which the CRO market size was US $44.6 billion, accounting for 43%, and the C (D) MO market size was US $59.5 billion, accounting for 57%.</p><p>In the next five years, the global CRO + C (D) MO industry will continue to maintain rapid growth. In 2022, the scale of the global pharmaceutical outsourcing industry will reach US $178.4 billion, with an average annual compound growth rate of 11.4%.<img src=\"https://static.tigerbbs.com/18fba7f0a1b0e11022ec40ea3a216aba\" tg-width=\"499\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d15886781297933be5997e460da5d6e6\" tg-width=\"503\" tg-height=\"375\" referrerpolicy=\"no-referrer\">The scale of pharmaceutical outsourcing in China is expected to grow as follows, with an average annual growth rate of about 12%.<img src=\"https://static.tigerbbs.com/7c08a2a436bd1d9a1c8d15a883425160\" tg-width=\"510\" tg-height=\"358\" referrerpolicy=\"no-referrer\">One more thing, if we look at the sub-industries of CXO, there are two aspects worthy of everyone's attention: First, whether CRO companies are in the past or in the future<b>The development trend is far less than that of CDMO companies</b>； Second, the future competitiveness of CXO companies whose main income comes from international sources is far greater than that of companies with a low proportion of international income.</p><p>I won't go into details here. The pictures below are for your reference.<img src=\"https://static.tigerbbs.com/9e5ac5dd0c02a7acfe64445230f1c9e2\" tg-width=\"793\" tg-height=\"757\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/4d5a5959082d1d943a32d3d125279c3a\" tg-width=\"770\" tg-height=\"545\" referrerpolicy=\"no-referrer\">To sum up, there are two main factors in the global pharmaceutical market, including the Chinese market, that determine the future growth of the CXO track: First, the scale growth of the pharmaceutical market, especially the growth rate of innovative drug development; Second, the penetration rate of the pharmaceutical outsourcing market has increased. The growth rate of the global pharmaceutical market is expected to be 5%, and that of China is 8%. The current penetration rate is 55% globally and about 40% to 45% in China. At this point, the conclusion is self-evident.</p><p>Except for the top few first-line and highest-quality CXO companies, everyone else is doing it and cherishing it.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A brief discussion on the valuation bubble of CXO track</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA brief discussion on the valuation bubble of CXO track\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1026500124\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/4df70e92a2d64be896797ea06b5e676a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">阿尔法工场研究院 </p>\n<p class=\"h-time smaller\">2021-06-25 10:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><img src=\"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29\" tg-width=\"1080\" tg-height=\"721\" referrerpolicy=\"no-referrer\"><b>As the penetration rate of CXO increases, the growth rate of the industry will decline rapidly in the future.</b></p><p>Before chatting, let's talk about the conclusion: No matter which CXO stock you hold at present, the current pe of one or two hundred, the valuation is obviously a bubble, but the bubble does not mean that you need to take profits, but just to remind everyone. Wake up, have correct psychological expectations for future expectations.</p><p>The CXO track has undoubtedly been one of the highest quality tracks in A-shares in recent years, and one of these can even be removed.</p><p>The rapid development of domestic CXO gods in recent years has benefited from these factors: First, engineer dividends. The supply of undergraduate, master's and doctoral degrees in China is blowout and the labor cost is relatively low (only equivalent to 30%-50% of that in European and American countries). In addition, in recent years, leading talents in overseas related fields have returned to China to start businesses. The combination of the two has outstanding advantages.</p><p>2. The penetration rate of China's pharmaceutical outsourcing market was low in the past few years, and it was only about 35% in 2018.</p><p>3. Industrial transfer of international pharmaceutical R&D outsourcing services, but judging from the current increasing costs, the future speed of industrial transfer needs to be questioned.</p><p>4. In recent years, capital has invested crazily in domestic innovative drug companies.</p><p>There is no need to talk about other fundamentals in detail. Let's take a look at the future development potential.</p><p><b>01</b></p><p>The growth of CXO is closely related to the growth of innovative drug companies.<b>To judge the golden cycle of CXO, it must be inseparable from the development and growth cycle of innovative drugs.</b></p><p>From the perspective of mature foreign markets, the growth rate of drugs under development matches the growth rate of CXO. Let's take a look at the global and Chinese pharmaceutical market size:</p><p><img src=\"https://static.tigerbbs.com/97773744b4b5641959840aaa0410f500\" tg-width=\"516\" tg-height=\"348\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7b8157b70922b8885798ae8bec9850cf\" tg-width=\"514\" tg-height=\"341\" referrerpolicy=\"no-referrer\">The global pharmaceutical market size in 2016 was US $1,153.6 billion, and is expected to reach US $1,475.1 billion in 2021, with a compound growth rate of approximately 5%.</p><p>From a geographical point of view, the United States is still the largest pharmaceutical market in the world. In 2016, the US market accounted for approximately 38% of the global market during the same period. As the world's largest emerging market, China's market size has maintained rapid growth in recent years as demand has continued to increase. It is expected to reach US $178.2 billion by 2021, with a growth rate of about 8%.</p><p>Let's take a look at the financing situation of domestic biotechnology companies in recent years. The high point of financing and the high point of pharmaceutical outsourcing growth should be obviously correlated. As you can see from the figure below, 2019 and 2020 are the peak periods of financing, and the two years after the peak of financing should also be the peak of CXO track growth.<img src=\"https://static.tigerbbs.com/77382e31cfaea57bcbe2a6d0e0fd118c\" tg-width=\"506\" tg-height=\"349\" referrerpolicy=\"no-referrer\">Visually, 2020 and 2021 in the figure below will be the peak of domestic CXO performance growth.<img src=\"https://static.tigerbbs.com/9abb7b6623e38f03db5ab2fe4ec70af3\" tg-width=\"516\" tg-height=\"354\" referrerpolicy=\"no-referrer\">Let's take a look at the role of pharmaceutical outsourcing services while the pharmaceutical market is developing. At present, the penetration rate of foreign pharmaceutical R&D outsourcing has reached about 55%, while the penetration rate of domestic pharmaceutical R&D outsourcing is still around 40% to 45%.</p><p>That is to say, if there is no foreign market, then there is still 10 to 15% potential for domestic pharmaceutical outsourcing to be tapped in the future.</p><p>Judging from the actual penetration rate and expectations of pharmaceutical R&D outsourcing development, the growth exceeded expectations.<b>The ceiling for future development should be very low.</b>Some industry insiders predict that the penetration rate ceiling will be around 60% to 65% or even lower.<img src=\"https://static.tigerbbs.com/242f24b01dd6070eb041e944988dc3df\" tg-width=\"558\" tg-height=\"351\" referrerpolicy=\"no-referrer\">To add a picture of the penetration rate of domestic pharmaceutical outsourcing, I think it is a bit underestimated based on other data.<img src=\"https://static.tigerbbs.com/0b764f34f3aad9e995adfc0b88e3b44c\" tg-width=\"649\" tg-height=\"454\" referrerpolicy=\"no-referrer\"><b>The foreign pharmaceutical outsourcing market is already very mature. Compared with the domestic market, the growth rate of the track is much lower. According to authoritative data, the growth rate of CXO in a mature market is about 10%.</b></p><p><b>02</b></p><p>The global pharmaceutical outsourcing market exceeds US $100 billion, of which the chemical drug C (D) MO market accounts for the largest share, and the biological drug C (D) MO has the fastest growth rate. It is reported that the average annual compound growth rate from 2013 to 2017 is 10.3%, and the overall growth of the global pharmaceutical outsourcing market is steady.</p><p>The overall market size reached US $104.1 billion in 2017, of which the CRO market size was US $44.6 billion, accounting for 43%, and the C (D) MO market size was US $59.5 billion, accounting for 57%.</p><p>In the next five years, the global CRO + C (D) MO industry will continue to maintain rapid growth. In 2022, the scale of the global pharmaceutical outsourcing industry will reach US $178.4 billion, with an average annual compound growth rate of 11.4%.<img src=\"https://static.tigerbbs.com/18fba7f0a1b0e11022ec40ea3a216aba\" tg-width=\"499\" tg-height=\"375\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/d15886781297933be5997e460da5d6e6\" tg-width=\"503\" tg-height=\"375\" referrerpolicy=\"no-referrer\">The scale of pharmaceutical outsourcing in China is expected to grow as follows, with an average annual growth rate of about 12%.<img src=\"https://static.tigerbbs.com/7c08a2a436bd1d9a1c8d15a883425160\" tg-width=\"510\" tg-height=\"358\" referrerpolicy=\"no-referrer\">One more thing, if we look at the sub-industries of CXO, there are two aspects worthy of everyone's attention: First, whether CRO companies are in the past or in the future<b>The development trend is far less than that of CDMO companies</b>； Second, the future competitiveness of CXO companies whose main income comes from international sources is far greater than that of companies with a low proportion of international income.</p><p>I won't go into details here. The pictures below are for your reference.<img src=\"https://static.tigerbbs.com/9e5ac5dd0c02a7acfe64445230f1c9e2\" tg-width=\"793\" tg-height=\"757\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/4d5a5959082d1d943a32d3d125279c3a\" tg-width=\"770\" tg-height=\"545\" referrerpolicy=\"no-referrer\">To sum up, there are two main factors in the global pharmaceutical market, including the Chinese market, that determine the future growth of the CXO track: First, the scale growth of the pharmaceutical market, especially the growth rate of innovative drug development; Second, the penetration rate of the pharmaceutical outsourcing market has increased. The growth rate of the global pharmaceutical market is expected to be 5%, and that of China is 8%. The current penetration rate is 55% globally and about 40% to 45% in China. At this point, the conclusion is self-evident.</p><p>Except for the top few first-line and highest-quality CXO companies, everyone else is doing it and cherishing it.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/928c8711580d163a8c799df993db2d29","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198330093","content_text":"随着CXO渗透率的提高，未来行业增速将快速下降。\n聊之前，先说结论：目前无论你持有哪一只CXO股票，现在的一两百的pe，估值明显都已经是泡沫了，但泡沫不意味着要你止盈，只是要给大家提个醒，对未来期望有个正确的心理预期。\nCXO赛道这几年毫无疑问是A股无容置疑的最优质赛道之一，甚至可以把这个之一拿掉。\n这些年国内CXO众神的飞速发展得益于这几个因素：一、工程师红利。我国本硕博供给井喷且劳动力成本相对较低（只相当于欧美国家的30%-50%），加上这几年海外相关领域的领军人才回国创业，两相结合，优势凸显。\n二、前几年中国医药外包市场的渗透率较低，2018年才35%左右。\n三、国际医药研发外包服务的产业转移，但从目前不断增长的各种成本来看，未来的产业转移速度要打个疑问了。\n四、近几年资本给国内创新药公司的疯狂投入。\n其他基本面就不用细谈了，我们来看看未来的发展潜力吧。\n01\nCXO的增长是与创新药公司的增长息息相关的，要判断CXO的黄金周期必定离不开创新药的发展增长周期。\n从国外成熟市场来看，在研药物规模增速和CXO增速是相匹配的，我们来看看全球和中国的医药市场规模：\n2016年全球医药市场规模为11536亿美元，预计将在2021年达到14751亿美元，复合增速约5%。\n从地域来看，美国仍是世界上最大的医药市场，2016年美国市场规模约占同期全球市场38%的份额。而中国作为全球最大的新兴市场，近年随需求不断提升，其市场规模也保持高速增长，预计到2021年将达到1782亿美元，增速约8%。\n再来看看这几年国内生物科技公司的融资情况，融资的高点与医药外包增长高点应该是前后相关性很明显的。下图可以看到2019、2020年是融资的高峰期，融资高峰后的两年也应该是CXO赛道增长的高峰。目测下图2020年、2021年会是国内CXO业绩增长的高峰。再来看看医药市场发展的同时医药外包服务起到的作用有多大，目前国外医药研发外包的渗透率已达到55%左右，而国内的医药研发外包渗透率仍在40%到45%左右。\n也就是如果没有国外市场，那么未来国内医药外包还有10到15%的潜力可以挖掘。\n从医药研发外包发展的实际渗透率和预计来看，增长是超预期的。未来发展的天花板应该很低了，有行业人士预测渗透率天花板在60%到65%左右甚至更低。补充一张国内医药外包渗透率的图片，我觉得根据其他数据综合来看有点低估了。国外的医药外包市场已经非常成熟了，相比国内而言赛道增长速度是放低很多，从权威的数据来看，一个成熟的市场的CXO增长速度大概10%左右。\n02\n全球医药外包市场规模超千亿美元，其中化药C(D)MO市场规模占比最大，生物药C(D)MO增速最快。据悉，2013—2017年年均复合增长率10.3%，全球医药外包市场规模整体增长平稳。\n2017年总体市场规模达到1041亿美元，其中CRO市场规模446亿美元，占43%，C(D)MO市场规模595亿美元，占57%。\n未来5年，全球CRO+C(D)MO行业仍将保持高速增长，2022年全球医药外包行业规模将达1784亿美元，年均复合增长率达11.4%。中国的医药外包规模预计增长情况如下，大概年均增长率12%左右。再多说一句，如果从CXO的细分行业来看，有两个方面值得大家注意：一是CRO企业不管是以前还是未来的发展趋势都远不及CDMO企业；二是主要收入来源于国际的CXO企业未来竞争力远大于国际收入占比低的企业。\n这里就不展开细说了。下面图片给大家参考。综上来看，全球医药市场包括中国市场主要有两个主要因素决定了CXO赛道未来的增长情况：一是医药市场的规模增长，特别是创新药发展的增速；二是医药外包市场的渗透率增长。全球医药市场增长预期是5%，中国是8%，目前的渗透率，全球55%，中国是40%到45%左右。 聊到了这里，结论已经不言而喻了。\n除了头部几个一线的最优质的CXO企业，其他的大家且行且珍重。","news_type":1,"symbols_score_info":{"WX":0.9}},"isVote":1,"tweetType":1,"viewCount":1687,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122309831,"gmtCreate":1624595682423,"gmtModify":1703841324350,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586297136997911","authorIdStr":"3586297136997911"},"themes":[],"htmlText":"look&nbsp;","listText":"look&nbsp;","text":"look","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122309831","repostId":"1102925117","repostType":4,"repost":{"id":"1102925117","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624582814,"share":"https://ttm.financial/m/news/1102925117?lang=en_US&edition=fundamental","pubTime":"2021-06-25 09:00","market":"hk","language":"zh","title":"XPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39","url":"https://stock-news.laohu8.com/highlight/detail?id=1102925117","media":"老虎资讯综合","summary":"6月25日，小鹏汽车-W发布公告，公司于6月25日至6月30日招股；拟全球发售8500万股股份，其中香港发售股份425万股，国际发售股份8075万股，另有15%超额配股权；每股发行价不超过180港元，","content":"<p>June 25th,<a href=\"https://laohu8.com/S/09868\">XPeng Motor-W</a>Announced that the company will issue an IPO from June 25th to June 30th; It plans to sell 85 million shares globally, including 4.25 million shares offered in Hong Kong, 80.75 million shares offered internationally, and a 15% over-allotment option; The issue price per share does not exceed HK $180, each lot of trading unit is 100 shares, and the admission fee is about HK $18,181.39; The Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/1e2905fbe978b70a1fadc57bfb9804ec\" tg-width=\"891\" tg-height=\"622\" referrerpolicy=\"no-referrer\"></p><p>Subscription ladder:</p><p>There are 100 shares per lot, and the admission fee is HK $18,181.39.</p><p>The threshold for Group B is 30,000 shares, and the funds required for subscription are approximately HK $5,454,415.8.</p><p><img src=\"https://static.tigerbbs.com/a8dafe8d708afb61e06e25e0b275bf27\" tg-width=\"934\" tg-height=\"360\" referrerpolicy=\"no-referrer\"></p><p>Founded in 2015, XPeng Motors has developed into the country's leading smart electric vehicle company, listed on the New York Stock Exchange in August 2020. XPeng Motor is engaged in the design, research and development, manufacturing and marketing of smart electric vehicles in the PRC. According to IHS Markit, as of the Latest Practicable Date, the company is the only automobile company in China that independently develops full-stack autonomous driving technology and applies the software to mass-produced vehicles. The company is building a rapidly expanding and diversified portfolio of attractive smart electric vehicle models to meet the growing demand for smart electric vehicles and the differentiated needs of its broad customer base.</p><p>As of 2021Q1, XPeng Automobile has 178 sales stores and 61 service centers nationwide, covering 70 cities, and most of the stores are located in shopping malls. In terms of charging facility network layout, as of 2021Q1, there are 172 XPeng brand super charging stations across the country, covering 60 cities. The company offers a free charging plan to eligible car owners, and by the end of March, the plan has covered more than 140 cities.</p><p>In terms of financial data, the company achieved significant growth and strong operating results during the Track Record Period. From 2018 to 2020, the company's total revenue increased from 9.706 million yuan to 5.844 billion yuan. With strong revenue growth, the company's gross profit margin increased from (24.3%) in 2018 to 4.6% in 2020, turning positive. In the first quarter of 2021, the company recorded total revenue of 450 million yuan, net loss of 120 million yuan, and gross profit margin of 11.2%.</p><p><img src=\"https://static.tigerbbs.com/853e033a96dad5cd098377abcd2fede8\" tg-width=\"973\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>In terms of fund-raising purposes, based on the upper limit of the offer price of HK $180, the IPO is expected to receive net proceeds of approximately HK $15.039 billion from the global offering (after deducting underwriting commissions and other estimated expenses related to the global offering). The company intends to use the net proceeds from the share offer for the following purposes: approximately 45% is expected to be used to expand the company's product portfolio and develop more advanced technologies; About 35% is expected to be used to accelerate the company's business expansion by enhancing the company's brand awareness, acquiring customers through omni-channel marketing strategies, and increasing sales and service coverage in domestic and international markets; Approximately 10% is expected to be used to improve production capacity, including expanding production capacity, upgrading production facilities and developing production technology; Approximately 10% is expected to be used for general corporate purposes, including working capital.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng Automobile-W will launch its IPO today, and the first-hand admission fee is about HK $18,181.39\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-06-25 09:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>June 25th,<a href=\"https://laohu8.com/S/09868\">XPeng Motor-W</a>Announced that the company will issue an IPO from June 25th to June 30th; It plans to sell 85 million shares globally, including 4.25 million shares offered in Hong Kong, 80.75 million shares offered internationally, and a 15% over-allotment option; The issue price per share does not exceed HK $180, each lot of trading unit is 100 shares, and the admission fee is about HK $18,181.39; The Shares are expected to be listed on the Main Board of the Stock Exchange on July 7.</p><p><b>Tiger Trade will open for subscription at 11:30 [</b><a href=\"https://www-web.itiger.com/mi/ipo/index/hk/listing\" target=\"_blank\"><b>Subscription entrance</b></a><b>】</b></p><p><img src=\"https://static.tigerbbs.com/1e2905fbe978b70a1fadc57bfb9804ec\" tg-width=\"891\" tg-height=\"622\" referrerpolicy=\"no-referrer\"></p><p>Subscription ladder:</p><p>There are 100 shares per lot, and the admission fee is HK $18,181.39.</p><p>The threshold for Group B is 30,000 shares, and the funds required for subscription are approximately HK $5,454,415.8.</p><p><img src=\"https://static.tigerbbs.com/a8dafe8d708afb61e06e25e0b275bf27\" tg-width=\"934\" tg-height=\"360\" referrerpolicy=\"no-referrer\"></p><p>Founded in 2015, XPeng Motors has developed into the country's leading smart electric vehicle company, listed on the New York Stock Exchange in August 2020. XPeng Motor is engaged in the design, research and development, manufacturing and marketing of smart electric vehicles in the PRC. According to IHS Markit, as of the Latest Practicable Date, the company is the only automobile company in China that independently develops full-stack autonomous driving technology and applies the software to mass-produced vehicles. The company is building a rapidly expanding and diversified portfolio of attractive smart electric vehicle models to meet the growing demand for smart electric vehicles and the differentiated needs of its broad customer base.</p><p>As of 2021Q1, XPeng Automobile has 178 sales stores and 61 service centers nationwide, covering 70 cities, and most of the stores are located in shopping malls. In terms of charging facility network layout, as of 2021Q1, there are 172 XPeng brand super charging stations across the country, covering 60 cities. The company offers a free charging plan to eligible car owners, and by the end of March, the plan has covered more than 140 cities.</p><p>In terms of financial data, the company achieved significant growth and strong operating results during the Track Record Period. From 2018 to 2020, the company's total revenue increased from 9.706 million yuan to 5.844 billion yuan. With strong revenue growth, the company's gross profit margin increased from (24.3%) in 2018 to 4.6% in 2020, turning positive. In the first quarter of 2021, the company recorded total revenue of 450 million yuan, net loss of 120 million yuan, and gross profit margin of 11.2%.</p><p><img src=\"https://static.tigerbbs.com/853e033a96dad5cd098377abcd2fede8\" tg-width=\"973\" tg-height=\"762\" referrerpolicy=\"no-referrer\"></p><p>In terms of fund-raising purposes, based on the upper limit of the offer price of HK $180, the IPO is expected to receive net proceeds of approximately HK $15.039 billion from the global offering (after deducting underwriting commissions and other estimated expenses related to the global offering). The company intends to use the net proceeds from the share offer for the following purposes: approximately 45% is expected to be used to expand the company's product portfolio and develop more advanced technologies; About 35% is expected to be used to accelerate the company's business expansion by enhancing the company's brand awareness, acquiring customers through omni-channel marketing strategies, and increasing sales and service coverage in domestic and international markets; Approximately 10% is expected to be used to improve production capacity, including expanding production capacity, upgrading production facilities and developing production technology; Approximately 10% is expected to be used for general corporate purposes, including working capital.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8a7cf240033f083a329240e6179df017","relate_stocks":{"09868":"小鹏汽车-W","XPEV":"小鹏汽车"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102925117","content_text":"6月25日，小鹏汽车-W发布公告，公司于6月25日至6月30日招股；拟全球发售8500万股股份，其中香港发售股份425万股，国际发售股份8075万股，另有15%超额配股权；每股发行价不超过180港元，每手买卖单位100股，入场费约18181.39港元；预期股份将于7月7日于联交所主板挂牌上市。\nTiger Trade将于11:30开放申购【申购入口】\n\n申购阶梯：\n每手100股，入场费18181.39港元。\n乙组门槛为3万股，申购所需资金约5454415.8港元。\n\n小鹏汽车成立于2015年，目前已发展成中国领先的智能电动汽车公司，于2020年8月在纽交所上市。小鹏汽车在中国从事智能电动汽车的设计、研发、制造及营销。根据IHS Markit的数据，截至最后实际可行日期，公司是中国唯一一家自主开发全栈式自动驾驶技术，并在量产汽车上应用该软件的汽车公司。公司正在打造一个快速扩展、多元化的具有吸引力的智能电动汽车车型组合，以满足智能电动汽车日益增长的需求以及广大客户群的差异化需求。\n截至2021Q1，小鹏汽车全国销售门店达178家，服务中心达61家，覆盖70个城市，绝大多数门店均位于购物中心。充电设施网络布局方面，截至2021Q1，全国共有172座小鹏品牌超级充电站，覆盖60个城市。公司向符合条件的车主提供免费充电计划，截至3月底，该计划已覆盖超过140个城市。\n财务数据方面，于往绩记录期间，公司实现了显著的增长及强劲的经营业绩。2018年至2020年，公司总收入由970.6万元增长至58.44亿元。随着收入的强劲增长，公司毛利率从2018年的(24.3%)增长至2020年的4.6%，实现转正。2021年一季度，公司录得总收入4.50亿元，净亏损1.20亿元，毛利率达到11.2%。\n\n筹资用途方面，以发售价的上限180港元计算，此次IPO预计自全球发售收取所得款项净额约150.39亿港元（经扣除包销佣金及与全球发售有关的其他估计开支）。公司拟将股份发售所得款项净额用于以下用途：约45%预期将用于拓展公司的产品组合及开发更先进的技术；约35%预期将用于通过提升公司的品牌认知度，借助全渠道营销策略获取客户，以及在国内及国际市场增加销售及服务覆盖，来加速公司的业务扩张；约10%预期将用于提升生产能力，包括扩大产能、升级生产设施和开发生产技术；约10%预期将用于一般公司用途，包括用作运营资金。","news_type":1,"symbols_score_info":{"XPEV":0.9,"09868":0.9}},"isVote":1,"tweetType":1,"viewCount":1594,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163854576,"gmtCreate":1623876777695,"gmtModify":1703822108690,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586297136997911","authorIdStr":"3586297136997911"},"themes":[],"htmlText":"up","listText":"up","text":"up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163854576","repostId":"1174117014","repostType":4,"repost":{"id":"1174117014","kind":"news","weMediaInfo":{"introduction":"关注中国基金报，即时获取深度理财资讯","home_visible":1,"media_name":"中国基金报","id":"6","head_image":"https://static.tigerbbs.com/2b2c79a68beb44c7bc06ad7210091200"},"pubTimestamp":1623850133,"share":"https://ttm.financial/m/news/1174117014?lang=en_US&edition=fundamental","pubTime":"2021-06-16 21:28","market":"sh","language":"zh","title":"Funds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1174117014","media":"中国基金报","summary":"A股有上演“跳水”的节奏，上证指数、沪深300、深证成指分别下跌1.07%、1.67%、2.57%，创业板指更是一口气下跌4.18%。\n在这一背景下，“基金走势”又登上热搜，不少投资者在微博上讨论基金","content":"<p><div>A-shares have a \"diving\" rhythm. The Shanghai Composite Index, CSI 300, and Shenzhen Component Index fell by 1.07%, 1.67%, and 2.57% respectively, and the ChiNext Index fell by 4.18% in one go. Against this background, \"fund trend\" has become a hot search topic again, and many investors discussed the trend of fund net value on Weibo, which caused heated discussions. However, opportunities often arise amid market fluctuations. Fund Jun integrates Nanfang, Bosera, Harvest, China Merchants, China Europe, ICBC Credit Suisse, Cathay Pacific, Chuangjin Hexin, HSBC Jintrust, Nord, Debon, Yongying, Essence, Golden Eagle, Qianhai Kaiyuan and other 15 fund companies' market outlook views found that many...</p><p><a href=\"None\">Web link</a></div></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Funds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFunds are on the hot search again! The Growth Enterprise Market plummeted by more than 4%, interpretation of the hot line of the top 15 fund companies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/6\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/2b2c79a68beb44c7bc06ad7210091200);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">中国基金报 </p>\n<p class=\"h-time smaller\">2021-06-16 21:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><div>A-shares have a \"diving\" rhythm. The Shanghai Composite Index, CSI 300, and Shenzhen Component Index fell by 1.07%, 1.67%, and 2.57% respectively, and the ChiNext Index fell by 4.18% in one go. Against this background, \"fund trend\" has become a hot search topic again, and many investors discussed the trend of fund net value on Weibo, which caused heated discussions. However, opportunities often arise amid market fluctuations. Fund Jun integrates Nanfang, Bosera, Harvest, China Merchants, China Europe, ICBC Credit Suisse, Cathay Pacific, Chuangjin Hexin, HSBC Jintrust, Nord, Debon, Yongying, Essence, Golden Eagle, Qianhai Kaiyuan and other 15 fund companies' market outlook views found that many...</p><p><a href=\"None\">Web link</a></div></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"159915":"创业板","399006":"创业板指","000001.SH":"上证指数"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174117014","content_text":"A股有上演“跳水”的节奏，上证指数、沪深300、深证成指分别下跌1.07%、1.67%、2.57%，创业板指更是一口气下跌4.18%。\n在这一背景下，“基金走势”又登上热搜，不少投资者在微博上讨论基金净值走势引发热议。\n\n然而机遇往往在市场波动中出现，基金君综合南方、博时、嘉实、招商、中欧、工银瑞信、国泰、创金合信、汇丰晋信、诺德、德邦、永赢、安信、金鹰、前海开源等15家基金公司后市观点发现，多家基金公司认为调整直接诱因是晚间美联储将再次召开利率会议，市场对于未来一段时间美联储货币政策收紧的预期 逐步达成共识，因此这一调整体现出当前资金整体避险情绪浓厚。\n不过，不少人士认为市场调整不改大市场大趋势，也给市场布局机遇，2021年市场存在结构性机遇，比较看好科技、新能源、周期、消费、金融等。\n多因素引发市场调整\n究竟是什么引发了6月16日的市场大跌？不少人士提及美联储将再次召开利率会议，这引起市场担忧美联储货币政策收紧，叠加前期市场上涨带来的内在调整要求，引发了今日市场大跌。\n中欧基金表示，今日晚间美联储将再次召开利率会议，市场对于未来一段时间美联储货币政策收紧的预期 逐步达成共识，但紧缩幅度仍存在一定分歧，在此情形下，今日市场大幅调整体现出当前资金整体避险情绪浓厚。\n在近期指数窄幅震荡的情况下，主题板块表现十分活跃，市场成交也处于高位，显示部分活跃资金在不断寻找突破的方向，但在权重保持稳定的情形下，更多的表现出“打游击”的典型特征，个股震荡幅度显著增大，连续上涨的可能性较小。\n而国泰基金也认为，今天市场调整的主要原因在于市场对美联储Taper（逐渐缩减资产购买规模）的担忧。美联储议息会议临近，由于担忧美联储对Taper发表鹰派表态，投资者情绪受到影响，引发市场下跌。而前期市场涨幅较高的新能源车、光伏等行业首当其冲，回调显著；银行等低估值行业避险。\n博时基金表示，今日A股大幅下行，主要是由于维稳时间窗口期越来越窄、A股性价比较差、对负面消息敏感度提升所致。美国昨日公布的PPI和零售销售数据、以及正在召开的美联储会议，或也对市场造成了一定的扰动。\n年初以来，国内经济基本面维持良好的修复动能，工业生产和出口均维持较高的景气度，目前全球的通胀水平继续上行，我国的货币政策依然以稳健为主，流动性相对温和。未来A股或仍以震荡为主，市场风格或将更趋于均衡。在中国新经济结构背景下，未来或仍以结构性机会为主，部分板块和个股经过前期的调整，估值或已进入相对合理的区间，可适当关注性价比高的绩优股的机会。\n南方基金认为，整体来看，市场自三月底以来呈现回暖反弹的状态，光伏新能源、生物医药等行业不少个股已收复前期跌幅，甚至创下新高。进入六月份，部分资金在价格到达前高后选择获利了结，个股层面的博弈性质明显增加。与此同时，我们看到市场成交量在万亿水平维持了数日，反映出资金对于后市存在较大分歧。归其原因，主要是市场缺乏投资主线。因此才有了结构的快速轮动以及部分题材的持续炒作。\n招商基金表示，近期市场题材轮动加快，前期持续上涨的板块出现高位回落；指数方面连续走弱，权重板块无明显主动护盘动作，短期市场风险仍有待进一步释放。今日市场出现较为明显的调整，前期强势的电车、医药、周期调整幅度较大。调整的原因主要是前期部分板块涨幅较大、市场获利了结心理较重，而阶段性的流动性宽松程度已难以进一步加码，同时叠加美联储议息会议在即，海外不确定性有所增加。\n嘉实基金表示，第一、创业板从3月25日到6月15日，上涨23.8%，反弹幅度较大 ，本身有整固需要。第二、美国5月数据超预期，CPI同比增5%，PPI同比增6.6%，通胀预期强烈，市场对流动性有所担忧。第三、美国零售额同比下降，或降低美联储会议鹰派决策的可能性，最终美联储会议结果，会在北京时间明日凌晨发布，今日部分避险资金提前流出。不过，截至6月16日收盘，上证指数PE为14.1，处于历史相对低位，长期投资价值凸显。嘉实基金维持2021年结构性机会丰富的判断，相对看好消费、科技板块里的成长型中小市值公司，以及低估值的金融等顺周期板块。\n工银瑞信表示，今日市场下跌主要受市场担忧美联储议息会议结果、国家粮食和物资储备局分批投放铜铝锌等国家储备等因素的影响。明天凌晨将会公布美联储议息会议结果，市场担忧美联储出现“鹰派”表述。前期涨幅较多的新能源车、光伏、医药等行业明显回调。国家粮食和物资储备局公告，按照国务院常务会议关于做好大宗商品保供稳价工作部署，将于近期分批投放铜、铝、锌等国家储备。投放面向有色金属加工制造企业，实行公开竞价，相关工作由国家物资储备调节中心具体负责。\n虽然经济改善最快的阶段可能已经过去，但在PPI高位缓慢回落背景下盈利仍有一定支撑，全年A股盈利增速整体还将处于改善通道中。当前货币政策仍强调稳字当头，尚未出现明显转向，但政策在稳杠杆、控风险上的权重逐步加大，预计货币政策仍将延续信用端结构性收紧、货币端维持平稳的态势。当前主要指数估值水平处于历史相对高位，预计短期指数将维持震荡格局，以结构性机会为主。风险方面，关注海外疫情、美股波动性加大等海外不确定性。\n创金合信基金首席策略分析师、首席投资官助理王婧认为，今日两市集体下跌，前期热门板块医药、白酒、新能源、汽车等均出现较大幅度的回调。下跌的主要原因还是来自市场的内在调整要求。一季度市场出现较大波动，在3月下旬进入筑底期，并展开反弹。创业板作为反弹的主要领导指数，在四、五月已经积累了20%的涨幅，短期上涨过快后，调整也是必然现象。特别是接近前期高点附近，市场出现震荡整固，放慢上涨节奏也符合预期。部分市场参与者对七一之后行情的稳定性存在担忧，提前获利了结也是加大市场波动的原因之一。\n从经济环境来看，一季度美债利率超预期上涨，海外市场大幅波动传导至国内资产价格的风险再现的可能不大。尽管美国通胀超预期，但美债利率已回落至1.5%左右，美国流动性非常宽裕。美元流动性外溢推动人民币汇率持续走高，国内十年期国债利率中枢下移，国内资产价格大幅下行的风险不大。盈利方面，A股今年仍有结构性亮点，医药、消费、新能源、科技等细分行业中不乏高景气高成长性的赛道和品种，在整体市场增量资金不多，但总量仍属充裕的环境下，这些领域仍会持续创造超额收益。\n安信基金表示，受美联储政策会议即将召开影响，今日市场较为谨慎。从外部看，一方面，本周全球迎来“超级央行周”，而美国公布的5月CPI同比升5%，创2008年8月来新高。通胀压力较大的情况下，市场高度关注周四凌晨美联储FOMC公布的利率决议、政策声明及经济预期的内容，市场情绪趋于谨慎，隔夜美股也出现调整，提升A股避险情绪。目前市场普遍预计美联储将在此次决议上按兵不动。美联储可能会在8月或9月宣布缩减计划，并在明年初开始执行。\n从A股来看，A股前期出现了一轮强反弹行情，而近期美元指数在90附近企稳之后，汇率升值影响有所弱化。目前市场普遍谨慎，前期各大热点的热度均有所下降。蓄势等待、立足业绩和估值的匹配度，关注中报业绩是短中期的主要思路。\n诺德基金顾钰也认为市场下跌原因是近期部分行业上涨过快，属于正常回调。\n德邦基金直言，今日市场大跌，主要由于之前高风险偏好资金倾向于提前兑现，而且当前资金面略偏紧，也压制了风险偏好。海外方面，今日晚间将召开美联储议息会议，市场对Taper（收紧）也并无特别担忧，纳斯达克、英法德等指数都是新高状态。无论是基本面，还是消息层面，并无特别风险点，倾向于认为当前更多是风险偏好的扰动，后续深跌的可能性不大，市场风格或将重回成长，围绕行业景气度继续震荡上行。\n震荡不改市场中期趋势\n谈及近期市场，不少人士认为从全年维度看，市场仍存在结构性的做多机会，会维持震荡格局。\n南方基金表示，宏观流动性收紧与盈利基本面向上是今年两大主线。前者会挤压资金的风险偏好，进而对市场估值形成一定压制，而后者确保了市场的质地和韧性。同时，社会不同经济部门受疫情影响的程度存在较大差异，行业间景气分化明显。因此，政策全面收紧的概率不大，所以权益市场发生系统性风险的可能性低。\n中短期而言，市场会维持震荡格局，出现趋势性大涨大跌的概率不大，主要原因是当前市场整体情绪不算亢奋，部分结构表现出的过热现象会通过一定的轮动来消化。同时，资金端仍较为宽松，流动性环境并不差。中长期而言，我们继续保持乐观态度，国内股市运行中枢逐年抬升的趋势非常明显，医药消费科技是长期布局的主赛道。\n中欧基金表示，中国当前已步入由繁荣转向过热的经济阶段，预计地产和基建等传统投资端将逐渐向中长期趋势回归，增速环比下行。在此情境下对内需依赖度较高的周期行业后续的业绩爆发力 可能较海外偏弱，而新经济的盈利周期尚未大幅开启，市场预期较高时价格往往出现较大波动；国内政策回归正常化的趋势和经济增长环比趋缓的背景之下，全市场整体估值难有提升，此时应适当放低回报预期，而细分机会将来自高成长性带来的业绩增长。\n招商基金展望后市认为，从全年维度看，在国内外经济持续修复、通胀压力仍存的背景下政策回撤的方向仍较为明确，但考虑到国内外整体货币政策基调并未进一步收紧，且全球经济复苏前景良好，市场仍存在结构性的做多机会。继续关注宏观经济深度复苏，景气度改善的低估值顺周期品种如银行和上游资源股的修复机会；对于新能源、白酒等近期涨幅较大的高景气行业，仍需对于估值和基本面景气度的匹配程度给予更高的筛选要求；中长期资金可在回落企稳后布局中报高增长、估值相对合理的细分方向。\n上述诺德基金顾钰表示，对于未来市场，依旧持谨慎乐观的看法。当前各国纷纷进入疫苗注射阶段，同时部分国家也出现疫情的爆发，我国少数城市也出现疫情但相对可控，属于疫苗和疫情赛跑的后疫情时代。全球经济正在从疫情中恢复，企业盈利改善从数据中持续得到确认。但经济恢复还需一个过程，因此流动性短时间内快速收紧的概率也很小。在春节后的一轮市场调整之后，高估值的压力有所释放，基本面优秀并且业绩确定性和持续性强的优质公司有望是市场重点配置方向。\n从中长期来看，我国金融开放的力度加大，外资持续流入的趋势不变。国内房住不炒的思路延续，叠加理财产品打破刚兑，权益市场有望承接居民资产配置的需求。从结构上看，中长期看好景气度向上的方向如白酒为代表的大消费、医药、新能源汽车等。\n国泰基金展望未来表示，A股中性偏多、宽幅震荡的格局没有变化，出现单边熊市的概率相对较低。从宏观经济看，地产韧性较强，基建维稳，制造业持续恢复。出口方面，在全球疫情后复苏阶段，预计下半年出口仍将保持韧性，PPI增速预计在三季度保持高位，四季度小幅回落。流动性层面，社融增速预计在三季度企稳，货币政策将维持中性。基本面方面，今年中报和下半年A股基本面大概率会稳健向上，企业的盈利能力和成长性将成为下一阶段市场的核心逻辑。\n而永赢基金展望未来表示，短期而言本周重点关注美联储议息会议。结构上，在经济动能减弱叠加流动性宽松的环境中，短期市场重新寻求确定性，高景气品种是重要配置方向，也是内外资的共识，以新能源产业链和白酒为代表的业绩确定性较强的核心资产股表现靠前。另外，在流动性宽松的环境下，受益于“鸿蒙”概念相关的计算机和电子等成长板块可能也有阶段性机会。\n从中期来看，克制基于总量变化布局的冲动，可以利用震荡格局优化持仓结构。市场总体反弹延续还需要一些催化剂，比如紧缩预期消退、甚至是宽松预期发酵的配合，这或许很难出现。主要是3月以来资金宽松的逻辑很难持续，一方面财政节奏偏慢的因素可能在下半年有所改变，随着债券发行速度加快，市场利率上行压力加剧；另一方面，也与美元流动性宽松外溢的被动因素相关，下半年随着美国经济加速修复将支撑美元指数上行。因此，需要克制基于总量变化布局的冲动，可以利用震荡格局优化持仓结构，结构上挑选基本面改善较强以及2021年业绩确定性较强的板块及个股。\n金鹰基金表示，整体来看，今日市场回调主要反映对国内外流动性的担忧，风偏回落下资金选择落袋为安。展望后市，预计A股仍将保持高位震荡，下行空间有限。我们预计，央行仍将维持“稳货币、紧信用”的基调，国内流动性并未大幅度转向，投资者在等待美联储动向的进一步明朗。而在中报业绩的加持下，A股并不具备持续回调的动力。\n前海开源首席经济学家杨德龙表示，A股市场经过前一轮的大幅下跌之后出现了一轮反弹，前段时间市场的情绪一度上升，但结构性行情的特征依然是非常明显的，建议逢低布局的像白酒、中药、光伏、新能源汽车等行业的龙头股大幅上涨，个别白龙马股甚至创出历史新高，形成了比较强的赚钱效应。可以说每轮大跌都是抄底优质股票的时机，概莫能外。\n市场短期的调整主要是反映对于美联储货币政策可能变化的一种预期。一旦美联储议息会议结束，周四公布议息会议的结果是不会加息，继续保持当前宽松政策的话，A股可能会出现强劲回升。市场短期的走势主要是由投资者的情绪所决定，和基本面并没有太大的联系，而长期来看，做价值投资，做好公司的股东，才能够从长期获得好的回报。\n主要看好新能源、消费品等\n中欧基金表示，成长股整体仍显著高于价值股的估值水平，而在偏高估值压力之下，成长股的成长确定性较成长性更加重要，随着上半年业绩的逐步落地，此时依然可以关注业绩确定性较高的新 能源、智能车、医疗服务等行业回调时的投资机会。此外，海外经济复苏仍在驱动大宗商 品价格上涨，虽然国内周期品上行推动力在投资端增速预计环比收敛和政策干预之下或将 逐渐减弱，但周期行业中下游需求偏重外需的行业如化工和航运等预计仍具备一定空间。\n国泰基金表示，仍然看好科技与新能源、周期金融、必须消费。“稳货币、紧信用”阶段，具备产业逻辑驱动的成长股仍可以占优，关注碳中和长期受益的光伏、新能源车。尽管短期有所调整，但是市场流动性预期的改变并不改变基本面的事实，它们代表的是经济转型发展方向，基本面并未发生变化。此外，我们还关注周期金融板块中的电解铝、铜、银行；必选消费中，医药相对占优。\n对于基金投资来说，如果长期看好新能源板块，则不妨在市场阶段性调整的阶段低位布局；如果担忧市场震荡，也可以选择追求稳健收益的“固收+”类产品。\n汇丰晋信首席宏观及策略师闵良超认为，对于后市，我们依然看好新能源汽车产业链、以化工为代表的一部分周期行业、军工的一些细分子行业、以及大金融板块的投资机会。不过我们始终认为，今年市场不太可能出现类似2019、2020年这样的系统性行情，市场整体表现会更加均衡，也需要我们自下而上不断地去衡量基本面和估值的变化，动态地挖掘市场机会。\n永赢基金则关注三大方向，第一是沿着外需复苏关注服务、海外地产投资端以及耐用品的中间品等，内需关注服务、消费品（特别是兼顾价格传导能力，白酒汽车家电）、地产后周期（建材、轻工）、制造业投资（机械）；\n第二、一季报验证高景气的方向：电气设备（新能源汽车）、医药生物（医疗服务高增速的持续性更好）和电子（半导体和被动元件），可以选择性价比较高的细分板块；\n第三、重视未来5年的大主题碳中和对各行各业的影响，清洁能源、钢铁、电解铝、水泥玻璃等高耗能产业的影响深远。","news_type":1,"symbols_score_info":{"159915":0.9,"399006":0.9,"000001.SH":0.9}},"isVote":1,"tweetType":1,"viewCount":1559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183868518,"gmtCreate":1623322455934,"gmtModify":1704200848771,"author":{"id":"3586297136997911","authorId":"3586297136997911","name":"SHADOWLEE","avatar":"https://static.tigerbbs.com/a2f36a7dea38634fe3d043e6ed5a2b1d","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586297136997911","authorIdStr":"3586297136997911"},"themes":[],"htmlText":"hi ,nice to meet here","listText":"hi ,nice to meet here","text":"hi ,nice to meet here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183868518","isVote":1,"tweetType":1,"viewCount":1323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}